WO2005058339A1 - 血栓形成抑制用組成物 - Google Patents
血栓形成抑制用組成物 Download PDFInfo
- Publication number
- WO2005058339A1 WO2005058339A1 PCT/JP2004/017780 JP2004017780W WO2005058339A1 WO 2005058339 A1 WO2005058339 A1 WO 2005058339A1 JP 2004017780 W JP2004017780 W JP 2004017780W WO 2005058339 A1 WO2005058339 A1 WO 2005058339A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- platelet aggregation
- present
- extract
- thrombus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention relates to a composition for suppressing thrombus formation.
- a thrombus is a clot of blood formed in a blood vessel.
- a protein called fibrinogen is activated and converted into fibrin, which forms an insoluble polymer together with platelets, leukocytes, and the like to form a blood vessel. It can solidify on the inner wall.
- fibrinolytic enzyme that functions to dissolve the fibrin that forms the thrombus prevents thrombus.
- Thrombi include primary hemostasis (platelet aggregation) and secondary hemostasis (blood clotting).
- the rupture of the blood vessel causes bleeding, and the platelets adhere to the holes in the blood vessel wall and aggregate to stop bleeding for the time being. This is called primary hemostasis, and the resulting thrombus is called primary thrombus.
- the water-soluble coagulation factor (fibrinogen) in plasma becomes non-water-soluble (fibrin), which forms a fibrous web between platelets and strengthens the primary thrombus. This is called secondary hemostasis, and the resulting thrombus is called a secondary thrombus.
- Platelet aggregation occurs when collagen on the wall is exposed due to rupture of the blood vessel wall, platelets adhere to the exposed collagen, and platelets aggregate together.
- the mechanism of blood coagulation includes intrinsic coagulation and extrinsic coagulation. Endogenous coagulation involves contact of the factor XII with the negatively charged subendothelial tissue, activation of factor ⁇ , and then activation of factor X by activated factor ⁇ . The clotting factor is activated, and finally fibrinogen, a factor I, undergoes limited degradation by thrombin, the active form of factor ⁇ (protrobin), and becomes fibrin, forming a thrombus.
- Extrinsic coagulation is activated by tissue factor and factor VII, and from the activation of factor X, it shifts to the intrinsic system and the common coagulation mechanism, and finally the factor I, fibrinogen, is activated.
- Thrombin the active form of factor II (protrobin) undergoes limited degradation and becomes fibrin, forming a thrombus.
- the formed thrombus deposits on blood vessels, reduces the cross-sectional area of the blood vessels, and inhibits blood circulation.
- thrombosis Symptoms caused by thrombus in blood vessels are referred to as thrombosis in a broad sense (hereinafter, simply referred to as "thrombosis” refers to a thrombosis in a broad sense). It is divided into thrombosis and embolism in a narrow sense. Narrowly defined thrombosis is a condition in which blood clots partially or completely occlude blood flow at the site of formation. Embolism is a condition in which a blood clot is peeled off from the site of formation and moves by the blood flow, causing partial obstruction of blood flow at other locations. Refers to a condition caused by complete or complete obstruction.
- Such thrombosis causes various diseases depending on the site of the blood vessel in which the thrombus has occurred. Especially when it occurs in cerebrovascular or cardiovascular, serious symptoms such as stroke, cerebral hemorrhage, cerebral infarction, heart failure, myocardial infarction, cardiac paralysis occur, causing half paralysis and severe death. Sometimes.
- vWF von-willebrand factor
- Gplb vWF receptors
- platelets are activated by an agonist such as thrombin, for example, and bind to other platelets via fibrinogen by fibrinogen receptor (GpIIb-Ilia), causing platelet aggregation, Platelet thrombi are formed. Therefore, it is one important requirement for preventing thrombus formation whether the formation of a crosslink between collagen and Gplb by vWF or the binding of GpIIb-Ilia to other platelets via fibrinogen can be suppressed.
- adenosine diphosphate ADENOSINE 5, DIPHOSPHAPE SODIUM: ADP
- ADENOSINE 5 DIPHOSPHAPE SODIUM: ADP
- Antithrombotic agents include antiplatelet agents and anticoagulants.
- Antiplatelet agents are intended to suppress the function of platelets involved in the initial stage of thrombus formation, and many orally administrable drugs such as aspirin have been developed. It is used to prevent recurrence of myocardial infarction and the like, and to prevent occlusion after various bypass operations. It is used not as a therapeutic agent for thrombosis but as a thrombosis preventive agent.
- anticoagulants henolin, which acts by accelerating the inhibition of thrombin by antithrombin III, and perfurin, a coumarin derivative of an oral anticoagulant, are used clinically.
- Perhalin inhibits the generation of thrombin by inhibiting vitamin K-dependent ⁇ carboxylation after translation during prothrombin synthesis.
- heparin must be administered parenterally, which acts as a cofactor of antithrombin III and is ineffective without this inhibitor.
- Perfurin exerts its effects very slowly, and individual doses must be tested and adjusted frequently.
- These anticoagulants which are specific to thrombin alone, also inhibit other serine proteases, both of which can induce bleeding if not properly adjusted in dosage.
- eicosapentaenoic acid (II), prostacycline (PG12) derivatives, and the like have been commercialized.
- a plasminogen activator such as streptokinase or perokinase
- a thrombus is generated by the plasminogen activator.
- Intravenous injection into a patient Therapies that activate the thrombolytic system are commonly used. Although its thrombolytic effect has been demonstrated in a number of clinical trials, similar to antithrombotic agents or thrombosis-preventing agents, side effects such as systemic bleeding during treatment of thrombus with no specificity for thrombus are observed. is there.
- tissue-type plasminogen activator (tPA) was considered to be an ideal thrombolytic agent with high selectivity for thrombus, but as a result of actual application to clinical treatment, although there were differences, there were still side effects such as systemic bleeding.
- tPA tissue-type plasminogen activator
- the half-life in blood is very short, and the duration of the drug effect is short, so that the dose must be large in order to maintain the drug effect in the body, and the treatment cost is much higher than that of conventional thrombolytic agents. There are problems with high and high.
- Patent Document 2 a patent on a kiwifruit extract (for example, see Patent Document 2) has been disclosed, but has a drawback that its activity in a neutral region is weak.
- nuttokinase (for example, see Patent Document 3) is well known.
- Nattokinase has vitamin C, which has a thrombolytic effect but also contributes to the production of coagulation factors.
- Patent Document 1 JP-A-2002-171934 (page 2)
- Patent Document 2 JP-A-2003-171294 (pages 2-5)
- Patent Document 3 Japanese Patent Application Laid-Open No. 2004-65047 (page 3)
- An object of the present invention is to provide a composition for suppressing thrombus formation, which contains a predetermined plant component and can be used in foods and drinks, quasi-drugs, pharmaceuticals, and feeds. Means for solving the problem
- the present inventors have conducted various studies and researches on the purpose of searching for a thrombus formation-inhibiting component using various natural plants. As a result, the present inventors have found that Amla, tea, grape, ibiscus, horn fir, gymnema, hijiki, and The present inventors have found that a certain plant component derived from carrageenan has an excellent antithrombotic effect, and completed the present invention.
- the gist of the present invention is:
- an antithrombotic composition characterized by containing at least one selected from the group consisting of Amla fruit, fruit juice and extracts thereof,
- composition of inhibiting fibrin formation characterized by containing at least one selected from the group consisting of Amla fruit, fruit juice and extracts thereof,
- an antiplatelet aggregation composition comprising at least one selected from the group consisting of Amla fruit, fruit juice and extracts thereof,
- a platelet aggregation inhibiting composition characterized by containing at least one selected from the group consisting of Amla fruit, fruit juice and extracts thereof,
- An antithrombotic composition comprising a tea extract
- composition for anti-platelet aggregation characterized by containing an extract of tea
- an anticoagulant composition comprising at least one selected from the group consisting of hibiscus fruits, fruit juices, leaves and extracts thereof,
- composition for preventing platelet aggregation comprising at least one selected from the group consisting of hibiscus fruits, fruit juices, leaves and extracts thereof,
- composition for preventing platelet aggregation comprising at least one selected from the group consisting of hibiscus fruits, fruit juices, leaves and extracts thereof,
- composition of inhibiting platelet aggregation and thrombus characterized by containing at least one selected from the group consisting of fruit, fruit juice, seeds and extracts thereof,
- a composition for inhibiting platelet aggregation thrombus characterized by containing at least one selected from the group consisting of fruit, fruit juice, seeds and extracts thereof of fir fir,
- a thrombus formation inhibitor which comprises gymnema, an extract thereof, or a mixture thereof;
- an extrinsic anticoagulant composition characterized by containing hijiki, its extract or a mixture thereof;
- a thrombopreventive composition characterized by containing hijiki, an extract thereof or a mixture thereof;
- composition for preventing thrombus which comprises an enzymatically treated product of hijiki, its extract, or a mixture thereof;
- an antithrombotic agent comprising carrageenan
- a composition for suppressing thrombus formation which comprises the above-mentioned predetermined plant component having a thrombus formation inhibitory action. Since this component is derived from a natural plant that has been conventionally used by humans in daily eating habits, according to this composition, unlike conventional drugs, there is no side effect that causes bleeding in the body, and thrombus formation is performed safely. Inhibition can prevent cardiovascular diseases such as cerebral hemorrhage, cerebral infarction, myocardial infarction, arteriosclerosis and coronary artery disease.
- the composition for suppressing thrombus formation of the present invention can be applied to, for example, foods and drinks, quasi-drugs, pharmaceuticals, and feeds.
- the present invention generally provides a composition for inhibiting thrombus formation. More specifically, various compositions are provided depending on a plant component used as an active ingredient.
- the composition of the present invention may be the active ingredient itself. Hereinafter, the method will be described separately for each plant used.
- the raw materials of the composition of the present invention can be used singly or as a mixture of two or more.
- antiplatelet aggregation In this specification, the terms antiplatelet aggregation, platelet aggregation suppression, platelet aggregation prevention, and antiplatelet have the same meaning.
- an antithrombotic composition comprising, as an active ingredient, at least one selected from the group consisting of Amla fruits, fruit juices, and extracts thereof.
- Anti-platelet aggregation composition and platelet aggregation inhibitory composition Things are provided.
- composition of the present invention is based on the action of the above-mentioned Amlar component! / Power to exert its effect In the present invention, the following action was found for the first time with a powerful Amlar component.
- thrombin has a high effect of suppressing fibrin formation by fibrinogen at the final stage of thrombus formation.
- amlar used in the present invention is scientific name: Emblica officinal e or Phyllanthum emblica (Phyllanthus embilica),!,, ... To the Malaysian region and southern China, with India being considered the place of origin.
- each region or language has its own unique name. , Nerikai, Nerli, Tasha, Power Yura Power, Kemura Power, Nakhonbon etc. Is also called.
- Juice obtained by squeezing fruits is also used as an active ingredient.
- Juice may be used as juice powder or the like.
- the water-insoluble component is removed by extraction to increase the effect.
- Fruit juice is also used as an extraction raw material.
- the extract in the antithrombotic composition of the present invention is preferably prepared as follows.
- the extraction method is not particularly limited, such as the extraction solvent and the extraction temperature.
- the extraction solvent water, bases, acids, and other non-organic solvents such as saline can be used.
- it is at least one selected from the group consisting of water, a base, and an acid.
- an acid or a base is used as an extraction solvent, it is preferable to neutralize the extract.
- the salt generated by the neutralization reaction can be removed by a known method such as dialysis or gel filtration.
- water is used as the extraction solvent, it is more preferable to use water because the neutralization reaction as described above does not need to remove the generated salts as necessary.
- acids can be used without any particular limitation, but one or more selected from hydrochloric acid and sulfuric acid are preferable.
- the base most of the base can be used without any particular limitation. Preferably, one or a combination of two or more selected from sodium hydroxide and potassium hydroxide is used. is there. [0040]
- the concentration of the acid or base used for the extraction is not particularly limited, but is preferably a concentration of 0.01 to 0.5 mol, which varies depending on the strength of the acid or base. Usually, the acid or base is used as an aqueous solution at a strong concentration.
- the extraction solvent is preferably used in an amount of preferably 500 to 5000 parts by weight based on 100 parts by weight of the dried extraction raw material.
- the extraction temperature is preferably from 40 to 70 ° C. The extraction may be carried out still or with stirring.
- the drying operation in the present specification can be performed by maintaining the object to be dried in a dryer [eg, a blower constant temperature dryer (manufactured by Yamato)] at 60-110 ° C for 2-16 hours. it can.
- the drying target is maintained at 70 ° C for 10 hours for drying.
- the fruit juice or the extract obtained as described above (the extract-containing solution, hereinafter the same) can be used as it is, but by removing insoluble substances by filtration or centrifugation, the relative It is preferable because the antithrombotic effect is enhanced and the application range is expanded.
- the concentration of ethanol is not particularly limited, but is preferably 70-90% (vZv), more preferably 60-95% (vZv), in terms of yield and action.
- the term “precipitate” refers to a substance that precipitates when a liquid containing the precipitate is centrifuged at 25 ° C. at 2000 rpm or more.
- the extract can be used as it is, but if desired, it can be used after being dried and powdered by means such as spray drying or freeze drying.
- the content of the fruit of Amla in the antithrombotic composition of the present invention is preferably 10 to 100% by weight in terms of dry matter, more preferably in consideration of the convenience of use of the composition.
- the content of Amla juice is preferably 5 to 100% by weight in terms of dry matter, more preferably 10 to 95% by weight in consideration of the convenience of use of the composition.
- %, And the content of those extracts is preferably 1 to 100% by weight in terms of dry matter, Considering the convenience of use of the composition, it is more preferably 5-95% by weight.
- the antithrombotic composition of the present invention is one extracted from Amla fruit or juice using at least one selected from the group consisting of water, base, and acidity.
- a certain antithrombotic composition and an antithrombotic composition containing an extract of Amlar fruit or juice, or a precipitate obtained by fractionating ethanol from fruit juice are preferred.
- the extract in the fibrin formation-inhibiting composition of the present invention is preferably prepared as follows.
- the points other than those described below are the same as in the case of the antithrombotic composition.
- the extraction solvent water, a base, an acid, and other hydrophilic solvents can be used.
- the hydrophilic solvent lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, and butyl alcohol and acetone are preferable in terms of operability and extraction efficiency.
- Particularly preferred is at least one selected from the group consisting of water, a base, and an acid.
- the fruit juice or the extract is preferable because it removes insoluble substances by force filtration or centrifugation, which can be used as it is, since the action of inhibiting fibrin formation is relatively increased and the range of application is widened.
- the concentration of ethanol is not particularly limited, but is preferably from 60 to 80% (vZv), more preferably from 20 to 80% (vZv), from the viewpoint of improving the action.
- those obtained by purifying a precipitate obtained by digesting ethanol with chromatography or a column are preferable because they can be obtained as a fraction having a higher inhibitory action on fibrin formation.
- the column chromatography is not particularly limited, and examples thereof include ion exchange chromatography, gel filtration chromatography, hydrophobic chromatography, adsorption column chromatography, affinity chromatography, and reverse phase column chromatography. Chromatography, ion exchange columns, gel filtration columns, hydrophobic columns, and reversed phase columns can be used. Gel filtration chromatography or gel filtration column is desirable from the point of purification efficiency!
- the content of Amla fruit in the fibrin formation-inhibiting composition of the present invention is preferably 10 to 100% by weight in terms of dry matter, and more preferably in consideration of the convenience of use of the composition. It is preferably 20-90% by weight, and the content of Amla juice is preferably 5-100% by weight in terms of dry matter, more preferably 10% in consideration of the convenience of use of the composition.
- the content of these extracts is preferably 1 to 100% by weight in terms of dry matter, more preferably 5 to 95% by weight in consideration of the convenience of use of the composition. It is.
- the extract of Amlar fruit or juice is at least one selected from the group consisting of water, base, acid, and hydrophilic solvent of Amlar fruit or juice power.
- the extract in the anti-platelet aggregation composition of the present invention is preferably prepared as follows.
- the points other than those described below are the same as in the case of the antithrombotic composition.
- the fruit juice or the extract is preferable because the antiplatelet action is relatively increased by removing insoluble substances by force filtration or centrifugation that can be used as it is, and the range of application is widened.
- the supernatant (including the soluble fraction) obtained by removing the insoluble substance and then directly adding or concentrating the fruit juice or extract and then adding ethanol thereto has a further higher antiplatelet effect, and preferable.
- the concentration of ethanol is not particularly limited, but 10-30% (vZv) is more preferable, and 10-30% (vZv) is more preferable, from the viewpoint of improving the action.
- the term “supernatant” refers to a residual liquid obtained by removing a substance that precipitates when a liquid containing a precipitate is centrifuged at 25 ° C. and 2000 rpm or more.
- the content of Amla fruit in the anti-platelet aggregation composition of the present invention is preferably 10 to 100% by weight in terms of dry matter, more preferably in consideration of the convenience of use of the composition.
- the content of Amla juice is preferably 5 to 100% by weight in terms of dry matter, more preferably 10 to 95% in consideration of the convenience of use of the composition.
- the extract content is preferably 1 to 100% by weight in terms of dry matter, and more preferably 5 to 95% by weight in consideration of the convenience of use of the composition. You.
- the anti-platelet aggregation composition of the present invention is extracted from Amla fruit or juice using at least one selected from the group consisting of water, base, and acid.
- An anti-platelet aggregation composition, an extract of Amlar fruit or juice, or an antiplatelet aggregation composition containing a soluble fraction obtained by fractionating ethanol from fruit juice is preferred.
- the extract in the platelet aggregation inhibiting composition of the present invention is preferably prepared as follows.
- the points other than those described below are the same as those of the antithrombotic composition.
- the extraction solvent in addition to water, a base, an acid and the like, a hydrophilic solvent and acetone can be used.
- hydrophilic solvent at least one selected from the group consisting of lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopyl propyl alcohol and butyl alcohol is preferable in terms of operability and extraction efficiency. Particularly preferred is at least one selected from the group consisting of water, a base, and an acid.
- the fruit juice or the extract is preferably used because the insoluble substance and the solvent are removed by force filtration, centrifugation, and fractionation that can be used as they are, thereby increasing the antiplatelet action and widening the application range.
- the fruit juice or the extract may be subjected to distribution using an organic solvent as it is or after concentration, to obtain a solvent-soluble fraction of each.
- organic solvent include methyl alcohol, ethyl alcohol, ethanol, n-propynoleanol, isopropanolanol, lower alcohol such as butyl alcohol, and ethyl alcohol, butyl acetate, butyl acetate, methyl ether, methyl ether, and methyl isobutyl.
- Ketones, hexanes, acetone or black form can be used.
- concentration of these solvents is not particularly limited, but from the viewpoint of improving the yield and action, the final concentration is 20%.
- One 80% (v / v) is preferred, and 20-60% (v / v) is more preferred.
- chromatography or column purification using a hydrophobic resin having a phenol-based, styrene-based, acrylic acid-based, epoxyamine-based, pyridine-based, methacryl-based or the like as a base may be performed. Good.
- lower alcohols such as methyl alcohol, ethanol, alcohol, n-propinoleanol, isopropynoleanol, butyl alcohol, etc., or acetone alone or Can be used as an aqueous solution.
- the content of Amla fruit in the platelet aggregation-inhibiting composition of the present invention is preferably 10 to 100% by weight in terms of dry matter, and more preferably in consideration of the convenience of use of the composition. It is preferably 20-90% by weight, and the content of Amla juice is preferably 5-100% by weight in terms of dry matter, more preferably 10% in consideration of the convenience of use of the composition.
- the content of these extracts is preferably 1 to 100% by weight in terms of dry matter, more preferably 5 to 95% by weight in consideration of the convenience of use of the composition. It is.
- an extract of Amla fruit or juice is at least one selected from the group consisting of water, a base, an acid, a hydrophilic solvent, and acetone power from Amla fruit or juice.
- a platelet aggregation inhibitory composition which has been extracted using an organic solvent, preferably an organic solvent for an extract of Amlar fruit or juice, preferably methyl alcohol, ethyl alcohol, n-propynoleanol, isopropanolanol, isopropanolanol Platelets containing at least one selected from the group consisting of glue, butinoleanolone, ethyl acetate, butyl acetate, getyl ether, methyl ether, methyl isobutyl ketone, hexane, and black form force. Agglomeration inhibiting compositions are preferred.
- the yield and flavor can be improved by enzymatic treatment, and a highly effective product can be obtained. It is preferable to carry out an enzyme treatment before the extraction of the raw material and at the time of Z or extraction.
- the pH at the time of enzyme treatment can be appropriately selected based on the optimum pH and pH stability of the enzyme used.
- the temperature at the time of the treatment can be appropriately selected based on the optimum temperature and the temperature stability of the enzyme used.
- the enzyme used for the enzyme treatment of the present invention is not limited.
- pectinase senorylase, hemisenolerase, ⁇ -amylase, gnorecoamylase, manoletotriohydrolase, 13-amylase, transdarcosidase, lipase.
- Protease glutaminase, nuclease, deaminase, dextranase, gnorecosoxidase, lactase, tannase, chlorogenic acid esterase, pullulanase, trypsin, papain, rennet, phospholipase, etc. Or more types.
- one or two or more selected from actinase, senorelase, hemicenolase, protease, chlorogenic acid esterase, and tannase can be used in combination.
- the amount of the enzyme used is not particularly limited, it is preferable to use 0.05 to 2 parts by weight with respect to 100 parts by weight of the force-dried extraction raw material, which varies depending on the type of the enzyme.
- the enzyme treatment may be similarly performed on the fruit or fruit juice of Amla.
- composition of the present invention a composition containing an Amla fruit, juice or an extract thereof, which has been treated with an enzyme, is more preferable.
- the antithrombosis in the antithrombotic composition of the present invention is not particularly limited, but is preferably an action of suppressing the formation of a thrombus (anticoagulant action).
- the antithrombotic effect is measured, for example, by measuring active coagulation partial thromboplastin time (APTT), which is a method for measuring anticoagulant activity on an endogenous blood coagulation system, as shown in Test Example A-1 below. This can be confirmed.
- APTT active coagulation partial thromboplastin time
- the fibrin formation inhibitory effect of the fibrin formation inhibitory composition of the present invention can be measured, for example, as described in Test Example A, 11 below, by adding the fibrin formation inhibitory composition to 3 ml of a 0.7% fibrinogen test solution. After homogenizing 300 microliters of kafun ⁇ , add 300 microliters of thrombin TS (10 UZ ml), add fibrin, coagulate and form fibrin, measure the coagulation weight, and check the inhibition rate of fibrin formation. can do.
- the fibrin formation inhibition rate is usually preferably 20% or more, more preferably 30% or more.
- Anti-platelet aggregation in the anti-platelet aggregation composition of the present invention refers to suppressing platelet aggregation, and is also simply referred to as antiplatelet.
- Antiplatelet activity was measured using a platelet aggregometer (Platelet rich plasma) or collected blood, as shown in Test Example A'-1 below. Caused It can be confirmed by a method of measuring the platelet aggregation rate when a substance to be added (ADP, epinephrine, collagen, arachidonic acid, etc.) is prepared.
- Platelet aggregation suppression in the platelet aggregation suppressing composition of the present invention refers to suppression of platelet aggregation, and is also simply referred to as antiplatelet.
- Antiplatelet activity can be measured, for example, by using a whole blood platelet aggregometer (Aggrego meter) as shown in Test Example A- It can be confirmed by a method of measuring the platelet aggregation rate when ristocetin, an agonist causing platelet aggregation by formation, is added.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and is preferably foods and drinks or pharmaceuticals that can be easily contacted by humans. Details of these application examples will be described later.
- the intake of the composition of the present invention as a food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, and the like of the administration target individual. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the amount of the composition of the present invention to be taken as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ per 50 kg of human weight per person.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the administration method, disease symptoms, body weight, age, sex, and the like of the administration subject. Number of doses
- administration can be made once or several times a day.
- the dose of the composition of the present invention as a medicament is usually about 40 mg to 3 gZ days, preferably 100 to 500 mg Z days per 50 kg of body weight per adult, in terms of the dry weight of the active ingredient.
- the present invention provides a composition for antithrombosis and a composition for antiplatelet aggregation, characterized by containing a tea extract as an active ingredient.
- composition of the present invention exerts its effects on the basis of the action of the above-mentioned tea component, but in the present invention, the following action was found for the first time with such a tea component.
- APTT activated thrombopartial thromboplastin time
- the results of the platelet aggregation test showed that the effect of suppressing the formation of platelet aggregates was high. That is, with respect to the tea component, platelet aggregation when ADP, which is an agent for causing platelet aggregation by inducing a binding step with other platelets by GpIIb-Ilia via fibrinogen, and V, From the results of the so-called ADP-induced platelet aggregation studies, it was evident that the inhibitory effect of GpIIb-Ilia on the binding of fibrinogen to other platelets via platelets was highly effective in inhibiting platelet aggregation.
- the tea used in the present invention is not particularly limited, but botanically, green tea which is unfermented tea produced from leaves of a Camellia plant, oolong tea which is semi-fermented tea, and black tea which is fermented tea Is mentioned. Among them, it is preferable to use green tea, which is an unfermented tea, from the viewpoint of the effect.
- the tea extract of the present invention is preferably reduced in polyphenols, which are astringent components, from the viewpoint of flavor.
- the method for measuring the polyphenol content in the present invention is not particularly limited, and examples thereof include an iron tartrate colorimetric method and a Folin thiocarte method, and preferably an iron tartaric acid colorimetric method. Law is preferred.
- the polyphenol content is preferably 15% by weight or less, more preferably 10% by weight or less in the solid content of the tea extract from the viewpoint of taste.
- the residual power after extracting the polyphenols from tea water or hot water extract is exactly the same as the "polyphenol" of the present invention. Tea extract with reduced types of tea ".
- polyphenols are easily dissolved in a specific organic solvent! / And have a property! /, Therefore, for example, when fractionation is performed using a specific organic solvent, most Dissolved in water-insoluble fraction), almost contained in water fraction No longer.
- tea leaves or crushed tea leaves are extracted with water or hot water, and the ⁇ tea extraction in which polyphenols are reduced '' is determined from the water transfer fraction obtained by distributing the tea leaves into solvents such as ethyl acetate and acetone.
- Thing is obtained.
- the use of polyphenols has been increasing in view of the various functions possessed by the polyphenols, and the components obtained by extracting the polyphenols from hot water extract of tea are so-called by-products. (Or residue) and was discarded as it was with little or no effective use.
- the hot water extract of tea can be used without excess, thereby improving economic efficiency and It also has the advantage of reducing waste emissions.
- the tea extract of the present invention preferably has reduced caffeine that functions to increase the blood levels of prothrombin and fibrinogen, which cause blood coagulation.
- the method for measuring caffeine is not particularly limited, but includes, for example, high performance liquid chromatography.
- the caffeine content is preferably 2% by weight or less, more preferably 1% by weight or less, based on the solid content of the tea extract.
- the above-described method of separating a tea extract from a water fraction of a tea water or hot water extract obtained by partitioning the product with ethyl acetate or acetone can reduce caffeine simultaneously with polyphenol. preferable.
- the method for extracting tea is not particularly limited.
- the extraction solvent is preferably used in an amount of 500 to 5000 parts by weight based on 100 parts by weight of the dried extraction raw material. do it.
- the extraction temperature is preferably 40-100 ° C.
- the extraction may be performed by standing or under stirring.
- the solvent used for the extraction in this case may be the same or another solvent may be used.
- the extract described above can be used as it is by infiltration of insoluble substances by filtration or centrifugation.
- the removal of is preferable since the antithrombotic effect or the antiplatelet aggregation effect is enhanced and the application range is widened.
- a precipitate obtained by adding ethanol to the extract after removing the insoluble substance and recovering the precipitate is preferable because the antithrombotic effect or the antiplatelet aggregation effect is further enhanced.
- concentration of ethanol is not particularly limited, but from the viewpoint of improving yield and action, a final concentration of 10-50% (v / v) is preferred 15-45% (v / v) Is more preferred.
- the extract may be used as it is, or may be used after drying if desired.
- the content of the tea extract in the antithrombotic composition or antiplatelet aggregation composition of the present invention is preferably 5 to 100% by weight in terms of dry matter, and the convenience of use of the composition is high. In consideration of the above, the content is more preferably 10 to 90% by weight.
- the tea extract is a tea extract in which polyphenols are reduced, and the tea extract is caffeine.
- the composition is a tea extract having reduced amount of tea, and the tea extract is a precipitate obtained by further fractionating the tea extract having reduced polyphenols and Z or caffeine with ethanol. Things are preferred.
- the antithrombosis in the antithrombotic composition of the present invention is not particularly limited, but preferably has an action of suppressing the formation of thrombus (anticoagulant action).
- the measurement of the antithrombotic effect is not particularly limited. For example, as shown in Test Example B-1 below, in the method for measuring the anticoagulant activity on the endogenous blood coagulation system, the activity It can be confirmed by measuring thromboplastin time (APTT).
- Anti-platelet aggregation in the anti-platelet aggregation composition of the present invention refers to suppression of platelet aggregation, and is also simply referred to as antiplatelet.
- the anti-platelet activity was measured by using a platelet aggregometer (Aggregometer) to detect aggregation in platelet rich plasma or collected blood. It can be confirmed by a method of measuring the platelet aggregation rate when a substance to be induced (ADP, epinephrine, collagen, arachidonic acid, etc.) is cultivated.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and preferably is easily used by humans. Foods and drinks or pharmaceuticals that can be contacted are preferred. Details of these application examples will be described later.
- composition of the present invention as food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, etc. of the individual to be administered. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the intake amount of the composition of the present invention as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ per 50 kg of human body weight of the composition.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the administration method, disease symptoms, body weight, age, sex, and the like of the administration subject. Number of doses
- administration can be made once or several times a day.
- the dose of the composition of the present invention as a medicament is usually about 50 mg to 3 gZ days, preferably 100 to 500 mg Z days per 50 kg of body weight per adult, in terms of the dry weight of the active ingredient.
- an anti-coagulant composition comprising at least one selected from the group consisting of fruit, fruit juice, leaves and extracts thereof of ibiscus, ibiscus, A composition for preventing aggregation and a composition for preventing platelet aggregation are provided.
- composition of the present invention exerts its effects based on the action of the hibiscus component, and in the present invention, the following action was first discovered for the powerful hibiscus component.
- hibiscus component platelet aggregation upon addition of ADP, which is an agonist that causes platelet aggregation by inducing the binding step with other platelets by fibrinogen by GpIIb-Ilia, so-called ADP induction GpIIb—Ilia based on platelet aggregation test results It has been shown that inhibiting the stage of binding to other platelets via fibrinogen is highly effective in suppressing platelet aggregation and thrombus formation.
- ADP is an agonist that causes platelet aggregation by inducing the binding step with other platelets by fibrinogen by GpIIb-Ilia
- the hibiscus used in the present invention is scientifically named Hibiscus, and in its Japanese name it is called Bussouge.
- Hibiscus is an evergreen shrub belonging to the genus Azotaceae, which is derived from the ancient Egyptian beauty goddess Hibis. The place of origin is southern China, southern China's eastern India, the South Pacific Islands, and tropical Africa. Hibiscus has a refreshing acidity and has recently been used as a sauce in French and Italian cuisine.
- the edible hibiscus used as an herb has the scientific name 'Hibiscus Sabdariffa Z (UK) Roselle' (US) with Florida cranberries. This type is called and is cultivated in countries such as Jamaica, Sudan, Egypt, Thailand, China, Suriname, and Malaysia.
- a portion of a fruit valve or leaf derived from a calyx and a flower is used as the hibiscus site.
- the form thereof is not particularly limited, and may be any of fresh fruit, dried fruit, fruit powder, fresh leaf, dried leaf, dried leaf powder and the like.
- fruit juice or fruit powder it can be used as it is, but contains water-insoluble components such as fresh fruits, dried fruits, fresh leaves or dried leaves, so that the water-insoluble components must be removed by extraction. Is preferred.
- the extraction method is not particularly limited, such as the extraction solvent and the extraction temperature.
- the extraction solvent water, a base, an acid, a hydrophilic solvent, and acetone can be used.
- Hydrophilic solvent is methyl
- One or more selected from the group consisting of lower alcohols such as anoreconore, etinoleanorecone, n-propinoleanorecone, isopropinoleanorecone, and butyl alcohol are preferred in terms of operability and extraction efficiency.
- it is at least one selected from the group consisting of water, a base and an acid.
- the extraction solvent When an acid or a base is used as the extraction solvent, it is preferable to neutralize the extract.
- the salt generated by the neutralization reaction can be removed by a known method such as dialysis or gel filtration.
- water When water is used as the extraction solvent, it is more preferable to use water because the neutralization reaction as described above does not need to remove generated salts.
- acids that are not particularly limited can be used, but one or more selected from hydrochloric acid and sulfuric acid in terms of availability and operability. Are preferably used in combination.
- base most bases can be used without particular limitation.
- Sodium hydroxide and potassium hydroxide are preferably used alone or in combination.
- the concentration of the acid or base used for the extraction is not particularly limited whether it is before or after the extract is subjected to the enzyme treatment, and varies depending on the strength of the acid or base. From the viewpoint of extraction efficiency, it is preferable to use a concentration of 0.01 to 0.5 mol. Usually, the acid or base is used as an aqueous solution of strong concentration.
- the extraction solvent is preferably used in an amount of 500 to 5000 parts by weight based on 100 parts by weight of the dried extraction raw material.
- the extraction temperature is preferably from 40 to 70 ° C. The extraction may be carried out still or with stirring.
- the above-mentioned extract can be used as it is, but by removing insoluble substances and solvents by filtration, centrifugation and fractionation, the anticoagulant effect or the antiplatelet aggregation effect is increased, and the range of application is also increased. It is preferable because it spreads.
- the yield and flavor can be improved by enzymatic treatment in addition, and a highly effective product can be obtained. Therefore, it is preferable to perform an enzyme treatment before and / or at the time of extraction of the extraction raw material.
- the pH at the time of enzyme treatment can be appropriately selected based on the optimum pH and pH stability of the enzyme used.
- the temperature at the time of the treatment can be appropriately selected based on the optimum temperature and the temperature stability of the enzyme used.
- the enzyme used in the enzyme treatment of the present invention is not limited, but is not particularly limited as long as it is used for the food industry.
- one or two or more selected from actinase, senorelase, hemicenolase, protease, chlorogenic acid esterase, and tannase can be used in combination.
- the amount of the enzyme used is not particularly limited, it is preferable to use 0.05 to 2 parts by weight with respect to 100 parts by weight of the force-dried extraction raw material, which varies depending on the type of the enzyme.
- the enzymatic treatment may be similarly performed on the fruit, fruit juice or leaf of ibiscus.
- composition of the present invention a composition containing fruits, fruit juices, leaves or extracts thereof, which are obtained by enzymatic treatment, is more preferable.
- Organic solvents include lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, and butyl alcohol, ethyl acetate, butyl acetate, getyl ether, methyl ether, methyl isobutyl ketone, hexane, acetone, and chloroform. Can be used.
- a petroleum alcohol which can be combined with partitioning by another hydrophobic solvent, is preferable.
- concentration of these solvents is not particularly limited, but 20 to 80% (vZv) is more preferable, and 20 to 60% (v / v) is more preferable as the final concentration from the viewpoint of yield and effect.
- purification by chromatography or column using a hydrophobic resin based on phenol, styrene, acrylic acid, epoxyamine, pyridine, methacryl, etc. may be performed. Good.
- lower alcohols such as methyl alcohol, ethanol, alcohol, n-propinoleanol, isopropynoleanol, butyl alcohol, etc., or acetone alone or Can be used as an aqueous solution.
- the extract and the fraction can be used as they are, but if desired, they can be used after being dried and powdered by means such as spray drying or freeze drying.
- the content of the fruit of the nose or ibiscus in the anticoagulant composition of the present invention is preferably 10 to 100% by weight in terms of dry matter, and more considering the convenience of use of the composition. It is preferably 20-90% by weight, and the fruit and ibiscus juice content is preferably 5-100% by weight in terms of dry matter, more preferably considering the convenience of use of the composition. It is preferably 10-95% by weight, and the content of hibiscus leaves is preferably 10-1100% by weight in terms of dry matter, and more preferably 20-100% in consideration of the convenience of use of the composition. — 90% by weight, and the content of these extracts is preferably 110 to 100% by weight in terms of dry matter, more preferably 5 to 95% by weight in consideration of the convenience of use of the composition. %.
- the content of hibiscus fruit in the platelet aggregation preventive composition or platelet aggregation preventive composition of the present invention is preferably 10 to 100% by weight in terms of dry matter, and the convenience of use of the composition is high. considering also the, more preferably 20- 90 weight 0/0, the content of the fruit juice hibiscus, in terms of dry matter, preferably 5 to 100 wt%, the convenience of use of the composition In consideration of the above, the content is more preferably 10 to 95% by weight, and the leaf and ibiscus leaf content is preferably 10 to 100% by weight in terms of dry matter, which makes the use of the composition convenient. In consideration of the above, the content is more preferably 20 to 90% by weight, and the content of the extract is preferably 1 to 100% by weight in terms of dry matter, considering the convenience of use of the composition. , More preferably 5 to 95% by weight.
- the anticoagulant composition, platelet aggregation preventive composition or platelet aggregation preventive composition of the present invention may be obtained from extracts of fruit, fruit juice or leaves of ibiscus, fruit of ibiscus, A composition obtained by extracting at least one selected from the group consisting of water, a base, an acid, a hydrophilic solvent and acetone from fruit juice or leaves, and an organic solvent of hibiscus fruit, fruit juice or leaf extract, preferably Is at least one selected from the group consisting of methyl alcohol, ethyl alcohol, n- propyl alcohol, isopropyl alcohol, butyl alcohol, ethyl acetate, butyl acetate, ethyl ether, methyl ether, methyl isobutyl ketone, hexane, and chloroform. Compositions containing fractions by species are preferred.
- the anticoagulant effect of the anticoagulant composition of the present invention is, for example, as shown in Test Example C2 described below, a method of measuring anticoagulant activity on an endogenous blood coagulation system. It can be confirmed by measuring the thromboplastin time (APTT).
- APTT thromboplastin time
- Platelet aggregation in the composition for preventing platelet aggregation of the present invention refers to suppression of platelet aggregation, and is also simply referred to as antiplatelet.
- the anti-platelet activity was measured using a whole blood platelet aggregometer (Aggregometer) to collect blood from GpIIb-Ilia via fibrinogen, as shown in Test Example C'-1 below. It can be confirmed by a method of measuring the platelet aggregation rate when ADP, which is an agonist that causes platelet aggregation by inducing the platelet binding step, is added.
- Antiplatelet aggregation in the composition for preventing platelet aggregation of the present invention refers to suppression of platelet aggregation, and is also simply referred to as antiplatelet.
- the antiplatelet activity is determined by, for example, using a whole blood platelet aggregometer (Aggregometer) to form a cross-link between vWF and collagen and Gplb in the collected blood, as shown in Test Example C'1 below. It can be confirmed by a method of measuring the platelet aggregation rate when ristocetin, an agonist causing platelet aggregation, is added.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and is preferably foods and drinks or pharmaceuticals that can be easily contacted by humans. Details of these application examples will be described later.
- the intake of the composition of the present invention as a food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, and the like of the individual to be administered. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the amount of the composition of the present invention to be taken as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ, per 50 kg of body weight per person.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the method of administration, disease symptoms, weight, age, sex, and the like of the administration subject. There are no restrictions on the number of administrations, period, timing, etc. For example, administration can be performed once or several times a day.
- the dosage of the anticoagulant composition of the present invention as a medicament is the amount of the active ingredient on a dry weight basis, and is usually about 50 mg to 2 gZ days, preferably 100 to 500 mg / day per 50 kg of body weight per adult. It is said.
- the dose of the platelet aggregation-preventing composition or platelet aggregation-preventing composition of the present invention as a medicament is usually the amount of the active ingredient on a dry weight basis, and is usually about 40 mg to 3 gZ per 50 kg of body weight per adult. , Preferably 100-500 mgZ.
- a platelet-aggregated thrombus-suppressing composition comprising, as an active ingredient, at least one selected from the group consisting of red fir fruit, fruit juice, seed, and an extract thereof. And a composition for inhibiting platelet aggregation and thrombus.
- composition of the present invention exerts its effect based on the action of the above-mentioned fir fir component.
- the following effects were found for the strong fir fir component for the first time.
- platelet aggregation when ristocetin which is an agonist that causes platelet aggregation by vWF-induced cross-linking between collagen and Gplb, and platelet aggregation induced by ristocetin induced by vWF, Inhibition of platelet aggregation and thrombus formation by suppressing vWF cross-linking between collagen and Gplb all right.
- the fir tree fir used in the present invention is scientific name: Xanthium strumarium L., and is an annual plant belonging to the genus Fir tree genus Asteraceae, having a height of about 1 m and short bristles throughout.
- the seeds alternate with the stalks and are almost heart-shaped, pointed at the tip, irregularly cut at the seed margins, thicker and slightly harder with short hairs.
- yellow-green capes are attached to the branches.
- the male flower has a hard green sting on the upper side, and the female flower is on the lower side.
- the fruits are wrapped in bracts and have a sting around them, and are sprayed on clothes and animal hair.
- Gonami is a force of about 20 species in the world.
- the place of origin is the continent of Asia, and the power is widely distributed around the world, especially in the Americas.
- the genus name is Xanthos, which is derived from the Greek word yellow, because ancient Romans used it as a dye that dyes hair yellow. (Raw rubbing) "is also called. It is also called the English name "Cocklebur”.
- the dried fruit of the red fir is dried in the sun and used as a crude drug. It is used as a remedy for fever, sweating, and headache. In Europe and North Africa, it was used as livestock feed and as a drug to remove lymph gland swelling.
- fruits, fruit juices, calyxes, petals or seeds are used as the parts of the fir.
- the form is not particularly limited, in the case of fruits that are not immature fruits, ripe fruits
- the water-insoluble component is removed by extraction!
- dried fruits and dried seeds are used as an extraction raw material, they are preferably ground to a particle size of 40 mesh or less in order to increase extraction efficiency.
- the extraction method is not particularly limited, such as extraction solvent and extraction temperature.
- water, a base, an acid, a hydrophilic solvent, and acetone can be used.
- the hydrophilic solvent is at least one selected from the group consisting of lower alcohols such as methyl alcohol, ethanol, ethanol, n-propynoleanol, isopropynoleanol, and butyl alcohol. preferable. Particularly preferably, it is at least one selected from the group consisting of water, a base and an acid.
- the extraction solvent When an acid or a base is used as the extraction solvent, it is preferable to neutralize the extract.
- the salt generated by the neutralization reaction can be removed by a known method such as dialysis or gel filtration.
- water When water is used as the extraction solvent, it is more preferable to use water because the neutralization reaction as described above does not need to remove generated salts.
- acids can be used without particular limitation, but one or more selected from hydrochloric acid and sulfuric acid in terms of availability and operability. Are preferably used in combination.
- the base most of the base can be used without any particular limitation, but one selected from sodium hydroxide and potassium hydroxide or a combination of both is preferred.
- the concentration of the acid or base used for the extraction, whether before or after the enzyme treatment of the extract, is not particularly limited, and varies depending on the strength of the acid or base. From the viewpoint of extraction efficiency, it is preferable to use a concentration of 0.01 to 0.5 mol. Usually, the acid or base is used as an aqueous solution of strong concentration.
- the extraction solvent is preferably used in an amount of 500 to 5000 parts by weight based on 100 parts by weight of the dried extraction raw material.
- the extraction temperature is preferably from 40 to 70 ° C. The extraction may be carried out still or with stirring.
- the extract can be used as it is, but is preferably used because filtration, centrifugation, and fractionation remove the insoluble substance and the solvent, thereby increasing the antiplatelet aggregation effect and expanding the application range.
- the enzyme treatment in the extraction operation of the extract used for each composition of the present invention, Since the yield and flavor can be improved by the enzyme treatment and a highly effective product can be obtained, it is preferable to perform the enzyme treatment before the extraction of the raw material for extraction and at the time of Z or extraction.
- the pH at the time of enzyme treatment can be appropriately selected based on the optimum pH and pH stability of the enzyme used.
- the temperature at the time of the treatment can be appropriately selected based on the optimum temperature and the temperature stability of the enzyme used.
- the enzyme used in the enzyme treatment of the present invention is not limited, but is not particularly limited as long as it is used for the food industry.
- one or two or more selected from actinase, senorelase, hemicenolase, protease, chlorogenic acid esterase, and tannase can be used in combination.
- the amount of the enzyme used is not particularly limited, it is preferable to use 0.05 to 2 parts by weight with respect to 100 parts by weight of the force-dried extraction raw material, which varies depending on the type of the enzyme.
- the enzyme treatment may be similarly performed on the fruit, fruit juice or seed of the fir.
- composition of the present invention a composition containing a fruit, a juice, a seed, or an extract thereof, of a fir tree, which has been subjected to an enzyme treatment, is more preferable.
- Organic solvents include methyl alcohol, ethyl alcohol, n -propyl alcohol, isopropyl alcohol, lower alcohols such as butyl alcohol, ethyl acetate, butyl acetate, getyl ether, methyl ether, methyl isobutyl ketone, hexane, acetone, and acetone. Holm can be used.
- the concentration of these solvents is not particularly limited, but from the viewpoint of yield and effect, the final concentration is preferably 20-80% (v / v), more preferably 20-60% (v / v). preferable.
- purification by chromatography or column using a hydrophobic resin based on phenol, styrene, acrylic acid, epoxyamine, pyridine, methacryl, or the like may be performed. Good.
- lower alcohols such as methyl alcohol, ethanol, alcohol, n-propinoleanol, isopropynoleanol, butyl alcohol, etc., or acetone alone or Can be used as an aqueous solution.
- the extract and the fraction can be used as they are, but if desired, they can be used after being dried and powdered by means such as spray drying or freeze drying.
- the content of the fir tree fruit in the platelet aggregation thrombus inhibitory composition or platelet aggregation thrombus inhibitory composition of the present invention is preferably 10 to 100% by weight in terms of dry matter.
- the content is more preferably 20 to 90% by weight, and the content of red fir juice is preferably 5 to 100% by weight in terms of dry matter, and the convenience of use of the composition is also considered.
- the content is more preferably 10 to 95% by weight, and the content of fir fir seed is preferably 10 to 100% by weight in terms of dry matter, and considering the convenience of use of the composition,
- the content of these extracts is more preferably 20 to 90% by weight, and the content of the extract is preferably 1 to 100% by weight in terms of dry matter, more preferably in consideration of the convenience of use of the composition. 5-95% by weight.
- water, base, acid, and hydrophilic solvent can be extracted from the fir tree fruit, juice or seed.
- a solvent extracted from at least one selected from the group consisting of acetone and acetone, an organic solvent for the extract of red fir fruit, juice or seed preferably methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol.
- compositions Containing at least one fraction selected from the group consisting of butinoleanolone, butinole acetate, butinole acetate, butinoleate ethereone, methylinoether, methyl isobutyl ketone, hexane, and black form force.
- Compositions are preferred.
- Platelet aggregation thrombus suppression in the platelet aggregation thrombus suppression composition of the present invention refers to suppression of platelet aggregation and suppression of thrombus formation. Platelet aggregation is also simply referred to as antiplatelet.
- the antiplatelet activity was determined, for example, as shown in Test Example D-1 below.
- ADP an agonist that causes platelet aggregation by inducing the binding step of fibrinogen through fibrinogen to other platelets, was added to the collected blood. It can be confirmed by the method of measuring the platelet aggregation rate at the time.
- Platelet aggregation thrombus suppression in the composition for inhibiting platelet aggregation thrombus of the present invention refers to suppression of platelet aggregation and suppression of thrombus formation.
- Antiplatelet For example, as shown in Test Example D'-1 below, the anti-platelet activity was measured by using a whole blood platelet aggregometer (Aggregometer) to collect platelets by forming a cross-link between collagen and Gplb by vWF. It can be confirmed by a method of measuring the platelet aggregation rate when ristocetin which is an agglutinating agonist is added.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and is preferably foods and drinks or pharmaceuticals that can be easily contacted by humans. Details of these application examples will be described later.
- composition of the present invention as food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, and the like of the individual to be administered. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the amount of the composition of the present invention to be taken as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ per 50 kg human body weight per person.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the administration method, disease symptoms, weight, age, sex, and the like of the administration subject. Number of doses
- administration can be made once or several times a day.
- the dosage of the composition of the present invention as a pharmaceutical is usually about 40 mg to 3 gZ days, preferably 100 to 500 mg Z days per 50 kg of body weight per adult, in terms of the dry weight of the active ingredient.
- Gymnema an extract thereof or a mixture thereof is effectively synthesized.
- a thrombosis-suppressing agent characterized in that it is contained as a component.
- composition of the present invention exerts its effects based on the action of the gymnema component.
- the following action was found for the gymnema component for the first time.
- the results of the platelet aggregation test showed that the Gymnema component had a high effect of suppressing the formation of platelet aggregates. That is, for the Gymnema component, platelet aggregation when ADP, which is an agonist that causes platelet aggregation by inducing a binding step with other platelets via fibrinogen by GpIIb-Ilia, is added, V, so-called ADP-induced platelet aggregation test results showed that GpIIb-Ilia had a high inhibitory effect on platelet aggregation by inhibiting the step of binding to other platelets via fibrinogen.
- ADP which is an agonist that causes platelet aggregation by inducing a binding step with other platelets via fibrinogen by GpIIb-Ilia
- Gymnema used in the present invention is scientific name: Gymnema Sylvestre (Asclepidaceae), which is native to India and widely distributed from tropical to subtropical regions such as Indonesia and southeastern China. It is a plant belonging to the same family as potatoes, ikemas, and ivy, which also grows in Japan.
- one or more species selected from the group consisting of leaves, stems, and vines are generally used as gymnema sites.
- the form is not particularly limited. In the case of powder, it can be used as it is, but it is preferable that water-insoluble components are removed by extraction with water or the like!
- the extraction method is not particularly limited, such as the extraction solvent and the extraction temperature.
- the extraction solvent water, bases, acids, alcohols, and other non-organic solvents such as saline can be used.
- it is at least one selected from the group consisting of water, base, acid and alcohol.
- the extraction solvent When an acid or base is used as the extraction solvent, it is preferable to neutralize the extract.
- the salt generated by the neutralization reaction can be removed by a known method such as dialysis or gel filtration.
- water When water is used as the extraction solvent, it is more preferable to use water because the neutralization reaction as described above does not need to remove the generated salts as necessary.
- the acid used at this time is not particularly limited, and most acids can be used. However, preferably, one or a combination of both selected from hydrochloric acid and sulfuric acid is used.
- the base most of the bases can be used without particular limitation.
- the base is one or more selected from sodium hydroxide and potassium hydroxide. is there.
- the concentration of the acid or base used for the extraction is not particularly limited, and it is preferable to use a concentration of 0.01-0.5 mol of a force that varies depending on the strength of the acid or base.
- the acid or base is used as an aqueous solution at a vigorous concentration.
- the alcohol in the present invention is not particularly limited, but is preferably one that can be used for preparing a food or drink material, and more preferably ethanol, isopropyl alcohol, propylene glycol and glycerin. At least one selected from the group consisting of ethanol, and most preferably ethanol.
- the extraction solvent is preferably used in an amount of 500 to 5000 parts by weight based on 100 parts by weight of the dried extraction raw material.
- the extraction temperature is preferably from 40 to 70 ° C. The extraction may be carried out still or with stirring.
- the solvent used for extraction may be the same or another solvent may be used.
- the above-mentioned extract can be used as it is, but it is preferable because removal of insoluble substances by filtration or centrifugation increases the thrombus formation inhibitory effect and expands the range of application.
- a supernatant (including a soluble fraction) obtained by removing the insoluble substance, removing the intact solution or concentrating the extract, and then adding ethanol to the extract is preferable because the thrombus formation inhibitory effect is further enhanced.
- the concentration of ethanol is not particularly limited, but is more preferably 60-90% (v / v), preferably 10-95% (vZv) as the final concentration, from the viewpoint of yield and effect.
- the extract can be used as it is, but if desired, it can be used after being dried and powdered by means such as spray drying or freeze drying.
- the content of gymnema in the thrombus formation inhibitor of the present invention is preferably in terms of dry matter, 10 to 100% by weight, considering the convenience of use of the composition, more preferably 20 to 90% by weight, and the content of the extract is preferably 1 to 100% by weight in terms of dry matter. Considering the convenience of use of the composition, it is more preferably 5 to 95% by weight.
- the thrombus formation inhibitor of the present invention includes: a thrombus formation inhibitor obtained by extracting a Gymnema extract using at least one selected from the group consisting of water, a base, an acid, and an alcohol; And an extract of Gymnema, and a thrombus formation inhibitor which is a soluble fraction further fractionated with ethanol.
- the thrombus formation suppression in the thrombus formation inhibitor of the present invention is not particularly limited, but preferably refers to suppression of thrombus formation mainly by anti-platelet aggregation.
- Antiplatelet aggregation refers to the inhibition of platelet aggregation, and is also simply called antiplatelet.
- the antithrombotic effect is measured as an antiplatelet activity, for example, by using a platelet aggregometer (Aggregometer), as shown in Test Example E-1 below, to a platelet suspension (platelet rich plasma) or collected blood, It can be confirmed by a method of measuring the platelet aggregation rate when a substance that induces aggregation (ADP, epinephrine, collagen, arachidonic acid, etc.) is added.
- ADP epinephrine
- collagen epinephrine
- arachidonic acid etc.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and is preferably foods and drinks or pharmaceuticals that can be easily consumed by humans. Details of these application examples will be described later.
- composition of the present invention as food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, and the like of the individual to be administered. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the amount of the composition of the present invention to be taken as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ per 50 kg of human body weight of the composition.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the administration method, disease symptoms, body weight, age, sex, and the like of the administration subject. Number of doses
- administration can be made once or several times a day.
- the dose of the composition of the present invention as a pharmaceutical is determined by the amount of the active ingredient in dry weight. Usually, it is about 50 mg-2 gZ days, preferably 100-500 mgZ days per 50 kg of body weight per adult.
- an extrinsic coagulation-preventing composition a thrombus-preventing composition, and a thrombus-preventing composition, characterized in that the composition comprises, as an active ingredient, hijiki, its extract, or a mixture thereof.
- the composition comprises, as an active ingredient, hijiki, its extract, or a mixture thereof.
- composition of the present invention exerts its effects based on the action of the above-mentioned hijiki component.
- the following effects were found for the first time on a powerful hijiki component.
- hijiki used in the present invention is scientifically named “Hijikia fusi forumis", and is a brown algae or a seaweed belonging to the family of the genus Nissanwara. It is a special product of the sea near Japan distributed on the Pacific coast and the Seto Inland Sea south of Hidaka district in Hokkaido, the Sea of Japan west of Hyogo prefecture, and the coast of Kyushu. Dry matter is black-brown. Hijiki grows on rocky shores of the open ocean near the low tide line, the body is dark greenish brown, and the roots are well-developed in intertwined fibrous forms and grow on the rocks.
- the stem of the body is cartilaginous, columnar, 3-4 mm thick, 0.5-lmm long, with elongated columnar leaves and twigs jutting out from the stem, and the leaves are fleshy and flattened adults in juveniles
- the leaves are linear, 3-10 cm, often sharp and pointed, but often have a club-like shape with a bulging tip, and sometimes have a hollow, bubble-like shape, from spring to early summer. Thrive. There is a lot of astringency that cannot be eaten raw, but boiled in an iron kettle for several hours to remove the astringency, remove the pigment, and dry it with sunlight to dry it.
- the site of hijiki is not particularly limited, but a twig portion and a main shaft portion are preferably used.
- the form is not particularly limited, and may be any of raw hijiki, dried hijiki, dried hijiki, hijiki powder and the like.
- the hijiki powder contains a water-insoluble component that can be used as it is, it is preferable that the water-insoluble component has been removed by extraction.
- raw hijiki, dried hijiki or dried hijiki is used as an extraction raw material at the time of extraction, it is preferable to use one obtained by crushing and homogenizing with a mixer or the like in order to increase extraction efficiency.
- dried or dried hijiki When dried or dried hijiki is used as an extraction raw material, it is preferably ground to a particle size of 40 mesh or less in order to increase the extraction efficiency.
- the extraction method is not particularly limited, such as the extraction solvent and the extraction temperature.
- the extraction solvent water, a base, an acid, a hydrophilic solvent, and acetone can be used.
- the hydrophilic solvent is at least one selected from the group consisting of methyl alcohol, ethanol, ethanol, n-propynoleanol, isopropynoleanol, and lower alcohols such as butyl alcohol. preferable. Particularly preferred is at least one selected from the group consisting of water, a base, an acid and a hydrophilic solvent.
- the extraction solvent When an acid or a base is used as the extraction solvent, it is preferable to neutralize the extract.
- the salt generated by the neutralization reaction can be removed by a known method such as dialysis or gel filtration.
- water When water is used as the extraction solvent, it is more preferable to use water because the neutralization reaction as described above does not need to remove generated salts.
- the acid to be used at this time most acids can be used without particular limitation. However, it is preferable to select from hydrochloric acid and sulfuric acid in view of availability and operability. One or a combination of both.
- the base most of the base can be used without any particular limitation.
- one or more selected from sodium hydroxide and potassium hydroxide are used in combination. is there.
- the concentration of the acid or base used for the extraction varies depending on the strength of the acid or base, which is not particularly limited. However, from the viewpoint of operability and extraction efficiency, 0.01 to 0.5 mol of the acid or base is used. concentration It is preferred to use Usually, the acid or base is used as a strong concentration of the aqueous solution.
- the extraction solvent is preferably used in an amount of preferably 500 to 5000 parts by weight based on 100 parts by weight of the dried extraction raw material.
- the extraction temperature is preferably from 40 to 70 ° C. The extraction may be carried out still or with stirring.
- the enzyme treatment is preferable because the yield and flavor can be improved and a highly effective product can be obtained by the enzyme treatment.
- the pH at the time of the enzyme treatment can be appropriately selected based on the optimum pH and pH stability of the enzyme to be used.
- the temperature at the time of the treatment can be appropriately selected based on the optimum temperature and temperature stability of the enzyme.
- the enzyme used in the enzyme treatment of the present invention is not limited, but is not particularly limited as long as it is used for the food industry.
- Pectinase cellulase, hemicellulase, ⁇ -amylase, dalcoamylase, Maltotriohydrolase, j8-amylase, transgnorecosidase, lipase, protease, gnoretaminase, nuclease, deaminase, dextranase, glucose oxidase, ratatase, tannase, chlorogenic esterase, pullulanase, trypsin, papain, ren
- One or two selected from net, phospholipase A2 and the like can be used in combination.
- one or two kinds selected from peptidenase, senorylase, hemicenolase, protease, chlorogenic acid esterase and tannase can be used in combination.
- the amount of the enzyme used is not particularly limited, it varies depending on the type of the enzyme and the reaction conditions, but it is preferable to use 0.05 to 2 parts by weight per 100 parts by weight of the dried extraction raw material.
- the solvent used for extraction may be the same or another solvent may be used.
- the extract can be used as it is, but by removing insoluble substances and solvents by filtration, centrifugation and fractionation, the effect of preventing extrinsic coagulation or thrombus is enhanced, and the range of application is expanded. preferable.
- Organic solvents include lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, and butyl alcohol, ethyl acetate, butyl acetate, dimethyl ether, methyl ether, methyl isobutyl ketone, hexane, acetone and chloroform.
- the concentration of these solvents is not particularly limited, but is preferably 20 to 80% (vZv), more preferably 20 to 60% (vZv) as the final concentration, from the viewpoint of yield and effect.
- chromatography or column purification may be performed using a hydrophobic resin whose parent material is a phenol-based, styrene-based, acrylic acid-based, epoxyamine-based, pyridine-based, or methacrylic-based resin.
- a hydrophobic resin whose parent material is a phenol-based, styrene-based, acrylic acid-based, epoxyamine-based, pyridine-based, or methacrylic-based resin.
- lower alcohols such as methyl alcohol, ethyl alcohol, ethanol alcohol, n-propynoleanol, isopropynoleanol, butanol and acetone are used alone.
- it can be used as an aqueous solution.
- the extract and the fraction can be used as they are, but if desired, they can be used after being dried and powdered by means such as spray drying or freeze drying.
- the content of hijiki in the composition for preventing extrinsic coagulation, the composition for preventing thrombus, or the composition for preventing thrombus of the present invention is preferably 10 to 100% by weight in terms of dry matter, and the use of the composition is preferred. Considering the convenience of the composition, it is more preferably 20 to 90% by weight, and the content of the extract is preferably 1 to 100% by weight in terms of dry matter. Considering this, it is more preferably 5 to 95% by weight.
- a hijiki extract is selected from the group consisting of water, a base, an acid, a hydrophilic solvent, and acetone.
- An organic solvent of a composition extracted from at least one selected from the group or an extract of a hijiki extract preferably methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, butyl alcohol, ethyl acetate, butyl acetate, getyl ether
- Compositions containing at least one fraction selected from the group consisting of methyl ether, methyl isobutyl ketone, hexane, and methylform are preferred.
- an extract Enzyme-treated products are more preferable.
- the extrinsic anticoagulant effect of the extrinsic anticoagulant composition of the present invention is, for example, a method of measuring anticoagulant activity against an extrinsic blood coagulation system as shown in Test Example F-1 described below. It can be confirmed by measuring prothrombin time (PT).
- PT prothrombin time
- the antithrombotic effect of the thrombus prevention composition and the thrombus prevention composition of the present invention can be measured, for example, by measuring activated partial thromboplastin time (APTT), which is a method for measuring anticoagulant activity against an endogenous blood coagulation system. It can be confirmed by measuring.
- APTT activated partial thromboplastin time
- the effects of the thrombus prevention composition of the present invention are confirmed by Test Example F′-1 described below, and the effects of the thrombus prevention composition of the present invention are confirmed by Test Example F ′ ′-1 described below. be able to.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and is preferably foods and drinks or pharmaceuticals that can be easily consumed by humans. Details of these application examples will be described later.
- composition of the present invention as a food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, and the like of the administration target individual. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the amount of the composition of the present invention to be taken as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ, per 50 kg of human weight per person.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the administration method, disease symptoms, weight, age, sex, and the like of the administration subject. Number of doses
- administration can be made once or several times a day.
- the dosage of the exogenous anticoagulant composition of the present invention as a medicament is usually about 50 mg-2 gZ days, preferably 100-100 mg / kg body weight per adult, based on the amount of the active ingredient on a dry weight basis. 500mgZ said.
- the dosage of the thromboprophylaxis composition and the thrombus thrombosis prophylaxis composition of the present invention as a medicament is usually the amount of the active ingredient on a dry weight basis, and is usually about lmg-40m / 50kg body weight per adult person. gZ days, preferably 2-lOmgZ days.
- the present invention provides an antithrombotic agent characterized by containing carrageenan as an active ingredient.
- composition of the present invention exerts its effects based on the action of carrageenan.
- the following action of carrageenan was found for the first time.
- the carrageenan used in the present invention is a natural polymer substance having a molecular weight of 100,000-500, which is also extracted and purified from seaweed power such as Ibaranori, Giraffe, Ginnanso, Suginori, or Sinomata.
- carrageenan can be used.
- the carrageenan is once dissolved in water or hot water and then filtered to remove insoluble components.
- any of t -carrageenan, K-carrageenan, and eh-carrageenan can be used, and a combination of two or more can be used. From the viewpoint of the effect, ⁇ -force lagunan is more preferred, in which one or a combination of one or more ⁇ -force lagunan is preferred.
- the content of carrageenan in the antithrombotic agent of the present invention is preferably 11 to 11 in terms of dry matter.
- the content is more preferably 5 to 95% by weight in consideration of the convenience of use of the composition.
- the antithrombosis in the present invention is not particularly limited, but preferably has an action of suppressing thrombus formation (anticoagulant action).
- the antithrombotic effect can be measured, for example, by measuring the anticoagulant activity of the endogenous blood coagulation system by measuring the activated thrombus partial thromboplastin time ( ⁇ ), as shown in Test Example G-1 below. It can be confirmed.
- composition of the present invention can be applied to foods and drinks, pharmaceuticals, feeds, and the like, and is preferably foods and drinks or pharmaceuticals that can be easily consumed by humans. Details of these application examples will be described later.
- the intake of the composition of the present invention as food or drink may be appropriately adjusted depending on the individual case in consideration of the physical condition, weight, age, sex, and the like of the individual to be administered. There are no restrictions on the number of times, period, timing, etc. For example, it can be taken once or several times a day.
- the amount of the composition of the present invention to be taken as food or drink is generally 0.05 to 20 gZ, preferably 0.1 to 5 gZ per 50 kg of human body weight as the composition.
- the dose of the composition of the present invention as a medicament may be appropriately determined depending on the individual case in consideration of the administration method, disease symptoms, body weight, age, sex, and the like of the administration subject. Number of doses
- administration can be made once or several times a day.
- the dosage of the composition of the present invention as a pharmaceutical is usually about 50 mg to 2 gZ days, preferably 100 to 500 mg Z days per 50 kg of adult body weight per dry weight of the active ingredient.
- the components other than the active ingredient of the present invention in the composition for suppressing thrombus formation of the present invention described in (1)-(7) above include, for example, dextrin, cyclic dextrin, cluster dextrin, hardly digestible Dextrin, xanthan, guar, guar gum decomposition products, polysaccharides such as alginic acid, plant proteins such as soy protein, and decomposition products of plant proteins such as soy peptide, animal proteins such as egg yolk, egg white, whole egg, and the like.
- Known food ingredient components such as egg yolks, egg whites, degradation products of animal proteins such as whole egg peptides, lactose, and the like.
- the composition of the present invention can be produced by appropriately mixing those known components and the active ingredient of the present invention.
- the above components may be natural or synthetic.
- a food or drink comprising the composition for suppressing thrombus formation of the present invention.
- the composition for suppressing thrombus formation means any of the above-described compositions of the present invention.
- the food or drink in the present invention is not particularly limited as long as it is in a form that can be ingested orally, such as a solution, a suspension, a powder, and a solid molded product.
- the content of the composition for inhibiting thrombus formation of the present invention in the food or drink is usually 0.01 to 15% by weight, preferably 0.05 to 15% by weight. 10% by weight is more preferred.
- Such foods and drinks can be produced in accordance with the known composition and production method of foods and drinks except that the composition for suppressing thrombus formation of the present invention is added as a part of the raw materials.
- the foods and drinks of the present invention include instant foods, retort foods, canned foods, microwave oven foods, instant soups, miso soups, instant foods such as freeze-dried foods, soft drinks, and fruit juices.
- Seasonings such as soup, curry stew, etc., processed fats and oils, butter, margarine, mayonnaise and other fats, milk drinks, yogurt Dairy products such as lactic acid bacteria drinks, ice creams and creams, frozen foods, processed fishery products such as fish meat ham 'sausages, fishery paste products, livestock meat hams; Examples include processed agricultural products such as pickles, boiled beans, and cereals, nutritional foods, tablets, capsules, and the like.
- Various nutrient components can be fortified in the thrombus formation-inhibiting composition of the present invention or the food or drink containing the composition.
- the nutritional components that can be fortified are not particularly limited, but include vitamin A, vitamin B, vitamin B, vitamin B, vitamin B, vitamin C, vitamin D, vitamin E, and niacin (nicotinic acid).
- vitamins such as pantothenic acid and folic acid; essential amino acids such as lysine, threonine and tributophan; minerals such as calcium, magnesium, iron, zinc and copper; and, for example, ⁇ -linolenic acid, EPA, DHA, evening primrose Approved as substances that contribute to human health, such as oil, octacosanol, casein phosphopeptide (CPP), casein calcium peptide (CCP), water-soluble dietary fiber, insoluble dietary fiber, and oligosaccharides, and other foods and food additives
- CPP casein phosphopeptide
- CCP casein calcium peptide
- water-soluble dietary fiber insoluble dietary fiber
- oligosaccharides and other foods and food additives
- One or more useful substances can be used.
- a quasi-drug and a pharmaceutical comprising the composition for suppressing thrombus formation of the present invention.
- the composition for suppressing thrombus formation means any of the above-described compositions of the present invention.
- the quasi-drugs and pharmaceuticals of the present invention include excipients and other additives suitable for oral or parenteral administration, and the thrombus formation-inhibiting composition of the present invention, and are formulated according to a conventional method.
- it can be prepared as an oral preparation or an injection.
- oral preparations such as oral solid preparations or oral liquid preparations, and most preferred are oral solid preparations that are easy to take and that are convenient to store and carry.
- the content of the composition for suppressing thrombus formation of the present invention in the quasi-drugs and the medicinal products is usually preferably from 0.1 to 300% by weight, more preferably from 11 to 100% by weight.
- Examples of the oral solid preparation include tablets, powders, fine granules, granules, capsules, pills, sustained-release preparations, and the like.
- suitable pharmacologically acceptable carriers eg, excipients (eg, starch, lactose, sucrose, calcium carbonate, calcium phosphate, etc.), binders (eg, starch, gum arabic, carboxymethylcellulose, hydroxy Pill cellulose, crystalline cellulose, alginic acid, gelatin, polybutylpyrrolidone, etc.), lubricants (eg, stearic acid, magnesium stearate, calcium stearate, etc.), disintegrants (eg, carboxymethyl cellulose, talc, etc.) and the like.
- a tablet, powder, fine granule, granule, capsule, pill, sustained release agent and the like can be produced by a conventional method.
- Oral liquid preparations include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and generally used inert diluents, for example, purified water. , And ethyl alcohol.
- Such preparations may contain, in addition to inert diluents, auxiliary agents such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Diluents for aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline.
- examples of diluents for water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethyl alcohol, and polysorbate 80.
- Injectables may further contain adjuvants such as preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (for example, radiose), and solubilizing agents (for example, glutamic acid, aspartic acid).
- a feed containing the composition for suppressing thrombus formation of the present invention is provided.
- the composition for inhibiting thrombus formation means any of the above-mentioned compositions of the present invention.
- the feed in the present invention can be produced according to a known feed composition and production method, except that the composition for suppressing thrombus formation of the present invention is incorporated as a part of the raw material.
- the content of the composition for inhibiting thrombus formation of the present invention in the feed is usually 0.01 to 15% by weight, preferably 0.05 to 10% by weight.
- Organisms to which the feed can be applied include, but are not particularly limited to, for example, farmed animals, pet animals, and the like, and farmed animals such as horses, horses, pigs, higgies, goats, ratadas, and llamas.
- Examples include domestic animals, laboratory animals such as mice, rats, guinea pigs, and egrets, and poultry such as birds, birds, ducks, turkeys and ostriches, and pet animals include dogs and cats.
- plants, their fruits, leaves, or seeds are used as active ingredients, and they can be used directly as they are, as well as dried, crushed, crushed, and the like. It is used in various forms after physical treatment in accordance with a known method. Therefore, in the present invention, those that have been subjected to such physical treatment are also treated as plants, their fruits, leaves, or seeds.
- the plant, its fruit, leaf, or seed after physical treatment alone or in combination of two or more, for example, dextrin, cyclic dextrin, cluster dextrin, indigestible dextrin, xanthan, guar, guar gum decomposition Products, polysaccharides such as alginic acid, plant proteins such as soy protein, and decomposed products of vegetable proteins such as soy peptide, animal proteins such as egg yolk, egg white, whole egg, and animal properties such as egg yolk, egg white, whole egg peptide Decomposed products of protein, excipients such as lactose, binders such as starch, cellulose, gum arabic, glucose, disintegrants such as gelatin, agar, cellulose, etc., magnesium stearate, sugar esters, glycerin fatty acid esters, etc.
- Those solidified by mixing with a lubricant can also be used as compositions, foods and drinks, quasi-drugs, drugs, Included in the fee.
- the dried Amler fruit was pulverized to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged, the supernatant was filtered, and the extract and the residue were separated. Two liters of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined to obtain the antithrombotic composition A of the present invention.
- the obtained extract was 70.8 g as a solid content, and the yield was 88.5%.
- the anticoagulant activity of the antithrombotic composition of the present invention was measured with a coagulometer (Coagulometer; manufactured by Sysmettas) using platelet poor plasma (PPP) separated from human blood.
- a coagulometer Coagulometer; manufactured by Sysmettas
- PPP platelet poor plasma
- Anticoagulant activity (%) ((sample APTT—control APTT) Z control APTT)
- the dried Amler fruit was pulverized to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged, the supernatant was filtered, and the extract and the residue were separated. Distilled water (2 L) was added to the residue, extracted once more under the same conditions, and each extract was combined and concentrated under reduced pressure to 200 mL. Ethanol was added to this concentrated solution to prepare 1 liter (final ethanol concentration: 80%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation, dried under reduced pressure, redissolved in 1 liter of water, filtered to remove insoluble components, and lyophilized from the filtrate to give 30.8 g of the antithrombotic composition B of the present invention (yield 38 .5%).
- Test example A 2 Confirmation of antithrombotic effect
- Example A-2 For the antithrombotic composition B obtained in Example A-2, APTT was measured at a concentration of 5 mgZmL in the same manner as in Test Example A-1. As a result, the APTT was 85.1 seconds, and the anticoagulant activity was 89.1%, confirming that the anticoagulant activity was higher than that of the antithrombotic composition A obtained by only water extraction.
- Example A-2 APTT was measured for the ethanol-soluble component in the same manner. As a result, the APTT was 48.0 seconds, the anticoagulant activity was 6.7%, and the antithrombotic activity was found. It was clear that the active fraction was contained in the ethanol precipitated fraction.
- Example A 1 1 Preparation of Fibrin Formation Inhibiting Composition 1
- the dried Amlar fruit was pulverized to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. Two liters of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined and freeze-dried to obtain 35.0 g of a fibrin formation-inhibiting composition A of the present invention. Yield was 43.8%.
- the fibrin formation inhibitory effect of the composition for inhibiting fibrin formation of the present invention was examined using a fibrinogen test solution and a thrombin test solution to determine the ratio of fibrin formation.
- Fibrin formation inhibition rate (%) ((total solution weight coagulation weight) Z total solution weight)
- the fibrin of the present invention having a solid content of 0 (control), 10, 25, or 40 mgZmL was used.
- the percent inhibition was measured using a formation inhibiting composition. The results are shown in Table 2 below.
- the dried Amlar fruit was crushed to 40 mesh or less, and 2 liters of distilled water was added to 100 g of the powder, 0.1 g of vectorinase and 0.1 g of tannase were added, followed by extraction at 55 ° C for 2 hours. . Thereafter, the enzyme was inactivated at 90 ° C. for 30 minutes. Thereafter, the mixture was centrifuged (3,000 rpm, 10 minutes), the supernatant was filtered, and the filtrate was spray-dried to obtain 45 g of the fibrin formation-inhibiting composition B of the present invention.
- the dried Amlar fruit was pulverized to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. Two liters of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined, and concentrated under reduced pressure to 200 ml. Ethanol was added to this concentrated solution to prepare 250 ml (final ethanol concentration: 20%), and the mixture was allowed to stand at 4 ° C for 24 hours to precipitate insoluble components. The supernatant was separated and removed by centrifugation (3000 rpm, 10 minutes), and the precipitate was freeze-dried to obtain 8.5 g of a fibrin formation-inhibiting composition C of the present invention.
- ethanol was added to a supernatant having a final ethanol concentration of 20% to precipitate the ethanol at a final concentration of 40%, and similarly, 4.6 g of the fibrin formation-inhibiting composition D of the present invention was prepared. Further, the same operation was repeated to make the final concentration of ethanol 60% and further 80% to obtain a precipitate, thereby obtaining a fibrin formation-inhibiting composition El. 3 g and F2.4 g of the present invention.
- the fibrin formation-inhibiting composition B obtained in Example A'-2 and the fibrin formation-inhibiting composition C-F obtained in Example A'-3 were each diluted with physiological saline to give lOmg / mL.
- the fibrin formation inhibitory effect was confirmed in the same manner as in Test Example A'-l at the sample concentration of
- the dried Amler fruit was pulverized to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged, the supernatant was filtered, and the extract and the residue were separated. 2 liters of distilled water was added to the residue, extracted once more under the same conditions, combined with each extract, freeze-dried, and treated with the anti-platelet aggregation composition of the present invention. 35 g of A was obtained.
- Test example A "-1 Confirmation of antiplatelet activity
- the antiplatelet activity of the antiplatelet aggregation composition of the present invention was determined as follows. Using an aggregometer (Aggregometer, manufactured by ISKE Inc.), add 80 ⁇ L of sample to 400 ⁇ L of platelet rich plasma of healthy people, and induce aggregation. ADP (lmgZmL solution) (20 ⁇ L) was added as a substance to be caused, and the platelet aggregation rate after 5 minutes was measured.
- Antiplatelet activity (%) ((platelet aggregation rate of control, platelet aggregation rate at the time of sample addition)
- Table 4 shows the results of measurement at 2.5, 5.0, and 7.5 mgZmL as sample concentrations.
- the dried Amler fruit was pulverized to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Then, centrifuge and filter the supernatant, extract And the residue was separated. Distilled water (2 L) was added to the residue, extracted once more under the same conditions, and each extract was combined and concentrated under reduced pressure to 200 mL. Ethanol was added to this concentrate to prepare 250 ml (final ethanol concentration: 20%), and the mixture was allowed to stand at 4 ° C for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation and removed. The supernatant was dried under reduced pressure, redissolved in 1 liter of water, filtered to remove insoluble components, and the filtrate was freeze-dried to obtain 29 g of the anti-platelet aggregation composition B of the present invention. Obtained.
- the anti-platelet activity was measured in the same manner as in Test Example A ′ ′′-1, at a sample concentration of 5. OmgZmL.
- the dried Amlar fruit was pulverized to 40 mesh or less, and 2 g of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. 2 L of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined and freeze-dried to obtain a platelet aggregation-inhibiting composition A35.Og of the present invention. Yield was 43.8%.
- the antiplatelet aggregation activity of the platelet aggregation inhibitory composition of the present invention was determined as follows. Using a whole blood platelet aggregometer (WBA-Neo: ISK Co., Ltd.), add 5 ⁇ L of sample to 200 ⁇ L of healthy human blood, and then use the final concentration S as a substance to induce aggregation. 22 ⁇ L of ristocetin sulfate (American Biochemical: 100 mg Z vial) adjusted to 10 ⁇ L was added, and the platelet aggregation rate after 5 minutes was measured.
- WBA-Neo ISK Co., Ltd.
- Antiplatelet aggregation activity (%) ((platelet aggregation rate of control and platelet aggregation rate at the time of sample addition)
- the sample was prepared by diluting platelet aggregation inhibitory composition A with distilled water to prepare 1.25, 2.5, and 5. Omg / mL.
- Table 6 shows the results of the measurement of the anti-platelet aggregation activity (%) in Example 1.
- the dried Amlar fruit was pulverized to 40 mesh or less, and 2 g of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. 2 L of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined and concentrated under reduced pressure to 200 mL. Ethyl alcohol was added to the concentrated solution to prepare 1 L (final ethyl alcohol concentration: 80%), and the mixture was allowed to stand at 4 ° C for 24 hours to precipitate insoluble components.
- the precipitate is separated and removed by centrifugation, the supernatant is concentrated under reduced pressure, redissolved in 1 L of water, filtered to remove insoluble components, and the filtrate is lyophilized and the platelet aggregation inhibiting composition B12.5 g of the present invention ( Yield 15.6%).
- the dried Amlar fruit was pulverized to 40 mesh or less, and 2 g of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. 2 L of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined and freeze-dried to obtain a dried product of about 37. Og. 1 L of ethyl alcohol was added to 35 g of the dried product, and the mixture was allowed to stand at 4 ° C. for 24 hours to precipitate insoluble components.
- the precipitate is separated and removed by centrifugation, the supernatant is concentrated under reduced pressure, redissolved in 1 L of water, filtered to remove insoluble components, and the filtrate is freeze-dried to obtain the platelet aggregation-inhibiting composition F3.5 g of the present invention.
- the dried Amlar fruit was pulverized to 40 mesh or less, and 2 g of distilled water was added to 80 g of the powder, followed by extraction at 55 ° C for 3 hours. Thereafter, the mixture was centrifuged, the supernatant was filtered, and the extract and the residue were separated. 2 L of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The extracts were combined and concentrated under reduced pressure to 200 mL. Ethyl acetate was added to this concentrated solution, and adjusted to 5 OOmL (final ethyl acetate concentration 60%). After stirring well, the mixture was allowed to stand at 4 ° C for 24 hours, then the ethyl acetate layer was separated and concentrated under reduced pressure. Thereafter, the filtrate was freeze-dried to obtain the platelet aggregation suppressing composition G12.5 g of the present invention.
- the dried Amler fruit was pulverized to 40 mesh or less, 2 L of distilled water was added to 100 g of the powder, 0.1 g of vectinase and 0.1 g of tannase were added, and the mixture was extracted at 55 ° C for 2 hours. Thereafter, the enzyme was inactivated at 90 ° C. for 30 minutes. Thereafter, the mixture was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the filtrate was spray-dried to obtain 5 g of the platelet aggregation inhibiting composition H4 of the present invention.
- Example III Platelet aggregation inhibitory composition B, C, D, E obtained in 1-2, Platelet aggregation inhibitory composition F obtained in Examples A,, 1-3, Example A ', 14
- the platelet aggregation inhibitory composition G obtained in 4 and the platelet aggregation inhibitory composition H obtained in Examples 5 and 8 were used at the concentration of 5.0 mgZmL as in Test Example A ''''-1. Platelet aggregation rate is measured by the method Aggregation activity was calculated. Table 7 shows the results.
- Example 5 5 g of platelet aggregation inhibitory composition obtained in A, 11, lactose 30 g, DHA-containing powdery fat (Suncoat DY-5; manufactured by Taiyo-Danigaku Co., Ltd.) 12 g, sucrose fatty acid ester 4 g, 4 g of fragrant perfume was mixed, and the mixture was pressure-formed using a rotary tableting machine to obtain 300 mg of a tablet-containing food or drink (tablet) containing the platelet aggregation inhibiting composition of the present invention.
- Example 5 5 g of platelet aggregation inhibitory composition B obtained in 1, 2 and 1Z5 concentrated grapefruit clear juice 2.lg, erythritol 30g, citrate crystal 2.5g, ternate citrate 0.5g, 0.5 g of L-ascorbic acid, 1.93 g of calcium lactate, 15 g of CCPO and 15 g of grapefruit flavor were mixed and dissolved in water to make a total volume of 100 mL, filled into a 100 mL bottle and sealed with a cap. Thereafter, the mixture was sterilized by heating at 90 ° C. for 30 minutes to obtain a food or drink containing the platelet aggregation suppressing composition of the present invention.
- Example ⁇ ′ ′′-8 Preparation of Beverage Containing Platelet Aggregation Inhibiting Composition (Vegetable Juice Mixed Beverage) [0309] Platelet aggregation inhibiting composition CO. 2 g obtained in Examples I, II, and guar gum decomposition (Sunfiber R; manufactured by Taisei-Danigaku Co., Ltd.) 3 g was added to a commercially available vegetable juice mixed beverage lOOmL and mixed and dissolved to obtain a platelet aggregation-inhibiting composition-containing food / beverage product (vegetable juice mixed beverage). .
- Unfiber R manufactured by Taisei-Danigaku Co., Ltd.
- Example 1 Platelet aggregation inhibitor composition Hlg obtained in 5, ⁇ , 1-5, 95 g of commercially available skim milk (manufactured by Meiji Dairies Co .; protein content 34%), and 35 g of commercially available salt-free butter (manufactured by Snow Brand Milk Products) was dissolved in 0.8 L of warm water, homogenized, and adjusted to a total volume of 1 L. Then, the mixture was sterilized by heating at 90 ° C for 15 minutes, cooled, inoculated with 3 g of commercially available lactic acid bacteria starter (manufactured by Nonzen) (2 g of Streptococcus thermophilus and Ratatobacillus vulgaritas lg), and mixed uniformly. After dispensing, filling, and sealing, and fermenting at 37 ° C for 20 hours, the mixture was cooled to obtain a yogurt containing the platelet aggregation inhibitory composition of the present invention.
- lactic acid bacteria starter manufactured by Nonzen
- MCT manufactured by Kao Corporation 45 g
- palm oil manufactured by Fuji Oil Co., Ltd.
- safflower oil manufactured by Taiyo Yushi Co., Ltd.
- lecithin manufactured by Taiyo Iridaku Co., Ltd.
- an antifoaming agent manufactured by Taiyo Kagaku
- the mixture was sterilized at 90 ° C. for 10 minutes, concentrated, and spray-dried to prepare about 260 g of an intermediate product powder.
- an intermediate product powder To 200 g of this intermediate product powder, 4 g of the platelet aggregation inhibitory composition C obtained in Examples A, 12, and 156 g, dextrin (manufactured by Matsutani-Danigaku Co., Ltd.) 156 g, and guar gum decomposition product (Sunfiber R; 18 g, small amounts of vitamins, minerals, and powdered flavors were added and uniformly mixed to obtain about 380 g of an oral liquid meal containing the platelet aggregation-inhibiting composition.
- Example 10 10 g of the platelet aggregation inhibitory composition obtained in ⁇ , -3, 5 g of crystalline cellulose, 13.8 g of corn starch, 32.5 g of lactose, and 3.3 g of hydroxypropyl cellulose were mixed and granulated. 1. Og of magnesium stearate was kneaded with the granules and uniformly mixed, and the mixture was pressure-formed using a rotary tableting machine, and one tablet of 130 mg of the platelet aggregation inhibiting composition of the present invention was obtained. A product-containing tablet was obtained.
- composition for inhibiting platelet aggregation used in Examples A, 6-1-12 is shown in the following Examples, which shows the antithrombotic composition, the fibrin formation inhibitory composition, and the antiplatelet aggregation composition of the present invention.
- Composition, thrombus prevention composition, thrombus prevention composition, exogenous coagulation prevention composition, anticoagulation composition, platelet aggregation prevention composition, platelet aggregation prevention composition, antithrombotic composition, antiplatelet aggregation A similar composition was produced by substituting the composition for inhibiting platelet aggregation, the composition for inhibiting platelet aggregation thrombus, the composition for inhibiting platelet aggregation thrombus, the antithrombotic agent, or the agent for inhibiting thrombus formation.
- Test example B 1 Confirmation of antithrombotic effect
- the anticoagulant activity of the antithrombotic composition of the present invention was measured with a coagulometer (Coagulometer; manufactured by Sysmex Corporation) using platelet poor plasma (PPP) separated from human blood.
- a coagulometer Coagulometer; manufactured by Sysmex Corporation
- PPP platelet poor plasma
- Anticoagulant activity (%) ((sample APTT—control APTT) Z control APTT)
- the antithrombotic composition of the present invention having a solid content of 0 (control), 1, 3, or 5 mgZmL was used. Were used to determine their activity. The results are shown in Table 8 below.
- Example B-1 In 100 g of the antithrombotic composition A obtained in Example B-1, 2 liters of water were dissolved in kato and dissolved, and ethanol was washed and prepared to reach 2.22 liters (final ethanol concentration 20%). After that, the mixture was allowed to stand at room temperature for 24 hours to precipitate insoluble components. The precipitate was separated by centrifugation, dried under reduced pressure, redissolved in 2 liters of water, filtered to remove insoluble components, and frozen. After being dried, 25 g (yield 25%) of the antithrombotic composition B of the present invention was obtained.
- Example B-2 APTT was measured for the antithrombotic composition BE obtained in Example B-2 at a concentration of 5 mgZmL in the same manner as in Test Example B-1. Table 9 shows the results.
- the antiplatelet activity of the composition for antiplatelet aggregation of the present invention was determined as follows. Using a platelet-rich plasma (400 ⁇ L) of a healthy person with 80 ⁇ L of sample, using a platelet aggregometer (manufactured by ISQUE) to induce aggregation. 20 ⁇ L of ADP (lmgZmL solution) was added as a substance to be caused, and the platelet aggregation rate after 5 minutes was measured.
- Antiplatelet activity (%) ((platelet aggregation rate of control, platelet aggregation rate at the time of sample addition)
- Table 10 shows the results of measurement at 2.5, 5.0, and 7.5 mgZmL as sample concentrations.
- the supernatant was treated in the same manner to obtain 7.3 g of anti-platelet aggregation composition C, which is an 80% ethanol-soluble fraction.
- Example II'-2 The anti-platelet aggregation compositions B and C obtained in Example II'-2 were measured for antiplatelet activity at a sample concentration of 5. Omg / mL in the same manner as in Test Example B'-1. Table 1 shows the results.
- the dried calyx and petals of rosacea and ibiscus were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and the mixture was extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure and then freeze-dried to obtain 29.8 g (19.9% yield) of the anticoagulant composition A of the present invention.
- the anticoagulant composition A obtained in Example C 1 and the anticoagulant composition B obtained in Example C2 were respectively used as solid content concentrations of 0, 0.1, 0.3, 0.5, 1. OmgZmL of the adjusted sample 10 / zL and PPP40 / zL were mixed and reacted at 37 ° C for 1 minute. Then, add 50 L of APTT reagent (manufactured by Kokusai Reagents), react at 37 ° C for 2 minutes, add 50 L of 25 mM calcium chloride and measure APTT in the same manner as in Test Example C-1. The henolin-like activity value was determined from the relational expression of the henolin-like activity value obtained in Test Example C1. Table 13 shows the results.
- the anticoagulant compositions A and B of the present invention showed that APTT increased as the concentration of the anticoagulant composition increased, and that the anticoagulant compositions used as anticoagulants
- the values of henolin-like activity converted to the average were 0.22 U / mg and 0.10 U / mg, respectively, and it was confirmed that the anti-coagulant effect was high especially in the fruit part.
- the precipitate was separated by centrifugation (8500 rpm, 10 minutes), the supernatant was concentrated under reduced pressure, and 1 L of distilled water was added to redissolve. The filtrate was filtered to remove insoluble components, and the filtrate was concentrated under reduced pressure and lyophilized to obtain 12.4 g (yield: 8.3%) of the platelet aggregation preventing composition C of the present invention.
- ethyl alcohol was added to the concentrate obtained in the same manner to precipitate insoluble components at final ethyl alcohol concentrations of 60% and 80%.
- a plate aggregation prevention composition D9.8 g (yield 6.5%) and E6.7 g (yield 4.5%) were obtained.
- APTT of the anticoagulant compositions C, D and E obtained in Example C3 was measured at a concentration of 0.5 mgZmL in the same manner as in Test Example C1.
- each APTT 55.6 s, 63.7 s and 65.1 s the henolin-like activity values were higher by fractionating 0.24 U / mg, 0.30 UZmg and 0.31 UZmg with ethyl alcohol. It was confirmed that a high anticoagulant effect was exhibited.
- Example C3 the APTT was measured in the same manner for the precipitated component at a final ethyl alcohol concentration of 20%. As a result, the APTT was 38.1 seconds, and the heparin-like activity value was 0.1%. It was found that the anticoagulable fraction was contained in the ethyl alcohol-soluble fraction.
- the dried calyx and petals of rosacea and ibiscus were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and the mixture was extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain 29.8 g (19.9% yield) of the platelet aggregation preventing composition A of the present invention.
- Test example C'1 Confirmation of anti-platelet aggregation activity 1
- the anti-platelet aggregation activity of the anti-platelet aggregation composition of the present invention was determined as follows. Using a whole blood platelet aggregometer (WBA-Neo: ISK), 200 U of healthy human blood and a 5 L sample were added, and the final concentration of the substance that caused aggregation was 10%. ADP (Sigma: 100 mgZ vial) (22 ⁇ L) adjusted to ⁇ ⁇ was added, and the platelet aggregation rate after 5 minutes was measured.
- WBA-Neo ISK
- Table 14 shows the measurement results of the samples prepared by diluting the platelet aggregation preventive composition with distilled water to prepare 1.25, 2.5, and 5. Omg / mL.
- the anti-platelet aggregation composition of the present invention showed that ADP-related GpIIb-Ilia inhibits the platelet binding stage to other platelets via fibrinogen. An aggregation effect was suggested. It was also confirmed that increasing the concentration of the anti-platelet aggregation composition increased the anti-platelet aggregation activity proportionally.
- the dried calyx and petals of rosacea and ibiscus were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and the mixture was extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure to 400 mL. Ethyl alcohol was added to the concentrated solution to prepare 500 mL (final ethyl alcohol concentration: 20%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation (8500 rpm, 10 minutes), the supernatant was concentrated under reduced pressure, and 1 L of distilled water was added to redissolve. The filtrate was filtered to remove insoluble components, and the filtrate was concentrated under reduced pressure and lyophilized to obtain 12.4 g (yield: 8.3%) of the platelet aggregation preventing composition C of the present invention.
- ethyl alcohol was added to the concentrate obtained in the same manner to precipitate insoluble components when the final ethyl alcohol concentration was 60% and 80%.
- the platelet aggregation preventing composition D9.8 g (yield 6.5%) and E6.7 g (yield 4.5%) were obtained.
- the platelet aggregation rate was measured at the concentration of Omg / mL in the same manner as in Test Example C'-l, and the antiplatelet aggregation was measured. Activity was calculated. As a result, it was confirmed that the anti-platelet aggregation activity (%) exhibited a higher anti-platelet aggregation effect by fractionating ethyl alcohol with 79.2, 81.4, and 83.6, respectively.
- Test Example C 1 1 Confirmation of antiplatelet aggregation activity 1
- the anti-platelet aggregation activity of the anti-platelet aggregation composition of the present invention was determined as follows. Using a whole blood platelet aggregometer (WBA-Neo: ISK), 200 U of healthy human blood and a 5 L sample were added, and the final concentration of the substance that caused aggregation was 10%. 22 ⁇ L of ristocetin sulfate (American Biochemical: 100 mgZ vial) adjusted to ⁇ was added, and the platelet aggregation rate after 5 minutes was measured. [0365] Separately, water (sample concentration OmgZmL) was added as a control, and the platelet aggregation rate was measured in the same manner.
- WBA-Neo ISK
- Antiplatelet aggregation activity (%) ((platelet aggregation rate of control and platelet aggregation rate at the time of sample addition)
- the sample was prepared by diluting the composition for preventing platelet aggregation with distilled water to obtain 1.25, 2.5, 5. Omg / m
- Table 15 shows the measurement results of those prepared as L.
- the dried calyx and petals of rosacea and ibiscus were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and the mixture was extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure to 400 mL. Ethyl alcohol was added to the concentrated solution to prepare 500 mL (final ethyl alcohol concentration: 20%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation (8500 rpm, 10 minutes), the supernatant was concentrated under reduced pressure, and 1 L of distilled water was added to redissolve. Then, filtration is performed to remove insoluble components, and the filtrate is concentrated under reduced pressure and frozen. After drying, 12.4 g (yield 8.3%) of the platelet aggregation preventing composition C of the present invention was obtained.
- ethyl alcohol was added to the concentrate obtained in the same manner to precipitate insoluble components at final ethyl alcohol concentrations of 60% and 80%.
- a plate aggregation prevention composition D9.8 g (yield 6.5%) and E6.7 g (yield 4.5%) were obtained.
- Test example C "2 Confirmation of anti-platelet aggregation activity 2
- the platelet aggregation rate was measured at the concentration of 5. Omg gmL by the same method as in Test Example C ′ ′-1. Platelet aggregation activity was calculated. As a result, it was confirmed that the anti-platelet aggregation activity (%) exhibited a higher anti-platelet aggregation effect by fractionating ethyl alcohol with 91.2, 93.4 and 94.6, respectively.
- the dried calyx and petals of the fir fir were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure and then freeze-dried to obtain the platelet aggregation-thrombotic inhibitory composition A26.4 g (17.6% yield) of the present invention.
- the dried fir seeds were pulverized to 20 mesh or less, 2 g of distilled water was added to 100 g of the powder, and extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain a platelet aggregation-thrombus inhibiting composition B14.lg (14.1% yield) of the present invention.
- the anti-platelet aggregation activity of the anti-platelet aggregation composition of the present invention was determined as follows. all Using a blood platelet aggregometer (WBA-Neo: ISK), add 200 U of healthy human blood and 5 L of sample, and then add a final concentration of 10 ⁇ M as a substance that induces agglutination. ADP (Sigma: 100 mgZ vial) adjusted to ⁇ was added in an amount of 22 ⁇ L, and the platelet aggregation rate after 5 minutes was measured.
- WBA-Neo ISK
- Antiplatelet aggregation activity (%) ((platelet aggregation rate of control and platelet aggregation rate at the time of sample addition)
- Table 16 shows the measurement results of the samples prepared by diluting the platelet aggregation thrombus inhibiting composition with distilled water to prepare 1.25, 2.5, and 5. Omg / mL.
- the platelet aggregation thrombus-suppressing composition of the present invention shows that ADP-related GpIIb-Ilia inhibits the binding step with other platelets via fibrinogen to inhibit the platelet aggregation.
- the platelet aggregation effect was suggested. It was also confirmed that increasing the concentration of the platelet aggregation thrombus-suppressing composition increased the antiplatelet aggregation activity proportionally.
- the dried calyx and petals of the fir fir were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and extracted at 100 ° C for 3 hours. Then, centrifuge (8500rpm, 10 minutes) The supernatant was filtered to separate the extract from the residue. The filtrate was concentrated under reduced pressure to 400 mL. Ethyl alcohol was added to this concentrate to prepare 500 mL (final ethyl alcohol concentration: 20%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components. The precipitate was separated by centrifugation (8500 rpm, 10 minutes), the supernatant was concentrated under reduced pressure, and 1 L of distilled water was added to redissolve.
- Example D-3 For the platelet aggregation thrombus inhibiting compositions C, D, and E obtained in Example D-3, 5.
- the platelet aggregation rate was measured at the concentration of 5. Omg gmL in the same manner as in Test Example D-1, and the antiplatelet aggregation activity was measured.
- the anti-platelet aggregation activity was 72.2 (%), 74.6 (%) and 76.4%, respectively.
- the anti-platelet aggregation activity was 72.2 (%), 74.6 (%) and 76.4%, respectively.
- Example D-3 the platelet aggregation rate was measured in the same manner for the precipitated component at a final ethyl alcohol concentration of 20%, and the antiplatelet aggregation activity was calculated. As a result, the antiplatelet aggregation activity was 10. 4 (%), indicating that the anti-platelet aggregation fraction was included in the ethyl alcohol-soluble fraction.
- the dried calyx and petals of the fir fir were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain 26.4 g (yield: 17.6%) of the composition A for inhibiting platelet aggregation and thrombus of the present invention.
- the dried fir seeds were pulverized to 20 mesh or less, 2 g of distilled water was added to 100 g of the powder, and extracted at 100 ° C for 3 hours. Then, centrifuge (8500 rpm, 10 minutes) The supernatant was filtered to separate the extract from the residue. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain a platelet aggregation thrombus inhibiting composition B14.lg (yield 14.1%) of the present invention.
- Test example D'- 1 Confirmation of anti-platelet aggregation activity 1
- the antiplatelet aggregation activity of the composition for inhibiting platelet aggregation thrombus of the present invention was determined as follows. Using a whole blood platelet aggregometer (WBA-Neo: ISK Co., Ltd.), add 5 ⁇ L of a sample to 200 ⁇ L of healthy human blood, and then add a final concentration of 10 ⁇ L to induce aggregation. 22 ⁇ L of ristocetin sulfate (American Biochemical: 100 mgZ vial) adjusted to ⁇ ⁇ was added, and the platelet aggregation rate after 5 minutes was measured.
- WBA-Neo ISK Co., Ltd.
- Antiplatelet aggregation activity (%) ((platelet aggregation rate of control and platelet aggregation rate at the time of sample addition)
- the sample was prepared by diluting the composition for suppressing platelet aggregation thrombus with distilled water to obtain 1.25, 2.5, or 5.
- Table 17 shows the measurement results of the sample prepared with ZmL.
- the dried calyx and petals of the fir fir were pulverized to 40 mesh or less, 3 L of distilled water was added to 150 g of the powder, and extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure to 400 mL. Ethyl alcohol was added to this concentrate to prepare 500 mL (final ethyl alcohol concentration: 20%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- Test example D'- 2 Confirmation of anti-platelet aggregation activity 2
- the platelet aggregation rate was measured in the same manner as in Test Example D'-1 at a concentration of 5. OmgZmL. The collecting activity was calculated. As a result, it was confirmed that the anti-platelet aggregation activity (%) exhibited a higher anti-platelet aggregation effect by fractionating ethyl alcohol with 90.5, 91.3 and 93.4, respectively.
- the antiplatelet activity of the thrombus formation inhibitor of the present invention was determined as follows. Using an aggregometer (Aggregometer, manufactured by ISKE), add 80 ⁇ L of the sample to 400 ⁇ L of a platelet rich plasma of healthy platelets, and induce aggregation. ADP (1 mgZmL solution) (20 ⁇ L) was added as a substance, and the platelet aggregation rate after 5 minutes was measured.
- aggregometer Aggregometer, manufactured by ISKE
- Antiplatelet activity (%) ((platelet aggregation rate of control, platelet aggregation rate at the time of sample addition)
- Table 18 shows the results of measurement at 2.5, 5.0, and 7.5 mgZmL as sample concentrations.
- the dried Gymnema powder was crushed to 40 mesh or less, and 2 liters of distilled water was added to 80 g of the powder and extracted at 55 ° C for 3 hours. Then, the extract and the residue were separated by filtration. Further, 2 liters of distilled water was added to the residue, extraction was repeated once again under the same conditions, and the respective extracts were combined and concentrated under reduced pressure to 200 ml. Ethanol was added to this concentrated solution to adjust to 1 liter (final ethanol concentration: 80%), and the mixture was allowed to stand at 4 ° C for 24 hours to precipitate insoluble components.
- Antithrombotic activity of thrombus formation inhibitors B and C obtained in Example E-2 was measured in the same manner as in Test Example E-1 at a sample concentration of 5. OmgZmL. Table 19 shows the results.
- the anti-extrinsic coagulation activity of the composition for preventing extrinsic coagulation of the present invention was determined as follows. Using a blood coagulation meter (Coagulometer; manufactured by Sysmetas), dilute standard heparin with distilled water to 40 L of a platelet rich plasma of healthy people with distilled water to obtain 0, 0.05, 0. A 10 L sample of heparin TS adjusted to 1, 0.2, and 0.3 UZmL was calored and reacted at 37 ° C for 1 minute. Thereafter, 100 L of PT reagent (manufactured by Kokusai Reagent Co., Ltd.) was added, and the time until the plasma was coagulated was measured to measure PT. Based on the relationship between the concentration of this heterogeneous reagent and PT, the following formula of the helin-like activity value (U / mg) was obtained. Heparin-like activity value (U, mg)
- the PT ratio at each sample concentration was calculated using the following formula using the concentration of the heterogeneous reagent solution OmgZmL as a control.
- PT ratio PT of PTZ control (Heparin TS concentration OmgZmL)
- the extrinsic anticoagulant composition A of the present invention had an average of 1.77 UZmg of henolin-like activity value converted to henol used as an anticoagulant, which was used as an anticoagulant. Yes, high, and it was confirmed that PT and anti-exogenous coagulation activity also increased in proportion to the increase in the concentration of the exogenous coagulation preventive composition.
- the dried hijiki was pulverized to 40 mesh or less, and 200 g of the powder was added with 6 L of distilled water and extracted at 100 ° C for 3 hours. After centrifugation (8500 rpm, 10 minutes), the supernatant was filtered to separate the extract from the residue. Thereafter, 6 L of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The combined extracts were concentrated under reduced pressure to 400 mL. Ethyl alcohol was added to this concentrated solution to prepare 500 mL (final ethyl alcohol concentration: 20%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation (8500 rpm, 10 minutes), and 1 L of distilled water was redissolved in the precipitate and filtered to remove insoluble components. The filtrate is concentrated under reduced pressure and freeze-dried to obtain the extrinsic coagulant of the present invention. 82.8 g (yield 16.4%) of the solid prophylactic composition B was obtained. Ethyl alcohol was added to the concentrate obtained in the same manner to precipitate insoluble components when the final ethyl alcohol concentration was adjusted to 60% and 80%. Prophylactic composition C28.4 g (14.2% yield) and D21.2 g (10.6% yield) were obtained.
- the dried hijiki was pulverized to 40 mesh or less, 100 g of the powder was mixed with 3 L of 50% ethyl alcohol water, and the mixture was allowed to stand at room temperature for 3 days for extraction. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain an exogenous anticoagulant composition F21.lg (yield: 21.1%) of the present invention.
- Exogenous anticoagulant composition A obtained in Example F-1, exogenous anticoagulant composition B, C, D, E obtained in Example F-2 and exogenous obtained in Example F-3 The PT was measured at a concentration of 0.2 mg ZmL as the solid concentration of the anticoagulant composition F.
- the heparin-like activity value and the PT ratio of each exogenous coagulation-preventing composition were determined by applying the formula for the heparin-like activity value (UZmg) of Test Example F1. Samples were also prepared in the same manner for the supernatant fraction at 80% ethyl alcohol in Example F-2, and the hen-like activity value and
- Extrinsic anticoagulant composition B 15.5 3.58 1.42
- Extrinsic anticoagulant composition F 15.8 3.77 1.45
- Example F-2 From Table 22, it was confirmed that the ethyl alcohol precipitated component obtained in Example F-2 exhibited a high heparin-like activity value, and the excellent anti-exogenous coagulation effect was included in the precipitated portion due to ethyl alcohol. That helped.
- the dried hijiki was pulverized to 40 mesh or less, 3 L of distilled water was added to 100 g of the powder, and extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain 23.8 g of the thrombus prevention composition A of the present invention. Yield was 23.8%.
- the antithrombotic effect of the antithrombotic composition A of the present invention was evaluated by measuring APTT using a blood coagulation meter (Coagulometer) using platelet poor plasma (PPP) isolated from human blood.
- APTT blood coagulation meter
- PPP platelet poor plasma
- the thrombopreventive composition A of the present invention increased the APTT with the increase in the concentration of the thrombopreventive composition, and was converted to hen used as an anticoagulant.
- Non-like activity value was 0.36 UZmg on average, confirming high anticoagulant effect
- the dried hijiki was pulverized to 40 mesh or less, and 200 g of the powder was added with 6 L of distilled water and extracted at 100 ° C for 3 hours. After centrifugation (8500 rpm, 10 minutes), the supernatant was filtered to separate the extract from the residue. Thereafter, 6 L of distilled water was added to the residue, and the mixture was extracted once more under the same conditions. The combined extracts were concentrated under reduced pressure to 400 mL. Ethanol was added to this concentrated solution to prepare 500 mL (final ethanol concentration: 20%), and then allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation (8500 rpm, 10 minutes), and the precipitate was re-dissolved by adding 1 L of distilled water and filtered to remove insoluble components.
- the filtrate was concentrated under reduced pressure and freeze-dried to obtain 16.4 g of the thrombus prevention composition B of the present invention.
- ethanol was added to the concentrate obtained in the same manner to precipitate insoluble components when the final ethanol concentration was 60% and 80%, and the same operation was carried out to carry out thrombosis prevention composition C21.4 g and the present invention. D25.2 g was obtained.
- ethanol was added to the supernatant having a final ethanol concentration of 60% to precipitate the ethanol at a final concentration of 80%, and the same operation was carried out to obtain 2.8 g of a thrombopreventive composition E of the present invention.
- APTT was measured in the same manner as in Test Example F'-1 at a concentration of 0.2 mgZmL as the solid concentration of the substance F.
- the test example F'-1 Heno Heno.
- the heparin-like activity value of each thrombus-preventing composition was determined by applying the formula to the phosphorus-like activity value (U / mg).
- a sample was prepared in the same manner as for the supernatant fraction with 80% ethanol in Example F'-2, and a non-like activity value was obtained. Table 25 shows the results.
- Example F From Table 25, it was confirmed that the ethanol precipitated components obtained in Example F and Example 12 exhibited high henolin-like activity values, indicating that the excellent anticoagulant effect was due to the ethanol extract of the water extract. Helped to be included in the part.
- the dried hijiki was pulverized to 40 mesh or less, 3 L of distilled water was added to 100 g of the powder, 0.1 g of protease was added, and the mixture was extracted at 55 ° C for 3 hours. Then the enzyme at 90 ° C for 30 minutes Deactivated. Then, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the filtrate was spray-dried to obtain 29.4 g of the thrombus preventing composition A of the present invention. Yield was 29.4% o
- the thrombus-preventing effect of the composition A for preventing thrombus of the present invention was evaluated by using a blood coagulation meter (Coagulometer; manufactured by Sysmettas Co., Ltd.) using platelet poor plasma (PPP) isolated from human blood. was measured and evaluated.
- a blood coagulation meter Coagulometer; manufactured by Sysmettas Co., Ltd.
- PPP platelet poor plasma
- APTT was measured by the same method using heparin adjusted to 0.05, 0.1, 0.2, and 0.3 UZmL as a sample as a control. From the relationship between the concentration of heparin and the APTT of heparin, the following formula for calculating the henone-like activity value (UZmg) was calculated. Norin-like activity values were determined. The results are shown in Table 27 below. Heparin-like activity value (U, mg)
- the composition A for preventing thrombosis of the present invention showed that APTT increased as the concentration of the composition for preventing thrombus increased, and was converted into henolin used as an anticoagulant.
- meter size EBEP heparin-like activity value average 0.521; was confirmed that indicated as 111 8 high, the anticoagulant effects.
- the dried hijiki was pulverized to 40 mesh or less, 3 L of distilled water was added to 100 g of the powder, 0.1 g of protease was further added, and the mixture was extracted at 55 ° C for 3 hours. Thereafter, the enzyme was inactivated at 90 ° C. for 30 minutes. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the filtrate was concentrated under reduced pressure to 200 mL. Add ethanol to this concentrate and adjust to 250 mL. After producing (final ethanol concentration 20%), the mixture was allowed to stand at room temperature for 24 hours to precipitate insoluble components.
- the precipitate was separated by centrifugation (8500 rpm, 10 minutes), 1 L of distilled water was added to the precipitate, and the precipitate was redissolved and filtered to remove insoluble components.
- the filtrate was concentrated under reduced pressure and freeze-dried to obtain 24.5 g of the thrombus prevention composition B of the present invention. Ethanol was added to the concentrate obtained in the same manner to precipitate insoluble components at a final ethanol concentration of 60%. .
- the dried hijiki was crushed to 40 mesh or less, 3 L of distilled water was added to 100 g of the powder, and the mixture was extracted at 100 ° C for 3 hours. Thereafter, the mixture was centrifuged (8500 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. The filtrate was concentrated under reduced pressure, and then freeze-dried to obtain 23.8 g of a comparative composition.
- Thrombosis-preventing composition A obtained in Examples F and -1; thrombus-preventing compositions B and C obtained in Examples F and -2 and Comparative Examples F and 11, respectively.
- APTT was measured for the comparative composition at a concentration of 0.2 mg ZmL as the solid concentration in the same manner as in Test Example F ′ ′′-1.
- the heparin-like activity value of each thrombus-preventing composition was determined by applying the formula for calculating the heparin-like activity value (UZmg) of Test Example F "-1. The results are shown in Table 28.
- the anticoagulant activity of the antithrombotic agent of the present invention was measured using a coagulometer (Coagulometer; manufactured by Sysmettas) using platelet poor plasma (PPP) separated from human blood.
- a coagulometer Coagulometer; manufactured by Sysmettas
- PPP platelet poor plasma
- the present invention provides a composition for suppressing thrombus formation, which comprises a predetermined plant component having a thrombus formation inhibitory action.
- the composition for suppressing thrombus formation of the present invention can be applied to, for example, foods and drinks, quasi-drugs, pharmaceuticals, and feeds.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/581,287 US7914830B2 (en) | 2003-12-04 | 2004-11-30 | Composition for inhibiting thrombosis |
CA002547590A CA2547590A1 (en) | 2003-12-04 | 2004-11-30 | Composition for inhibiting thrombosis |
EP04820510A EP1721533A4 (en) | 2003-12-04 | 2004-11-30 | COMPOSITION FOR INHIBITING THROMBOSIS |
Applications Claiming Priority (32)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003405449A JP2005162685A (ja) | 2003-12-04 | 2003-12-04 | 抗血栓用組成物 |
JP2003-405449 | 2003-12-04 | ||
JP2003405452A JP2005162686A (ja) | 2003-12-04 | 2003-12-04 | 抗血栓剤 |
JP2003-405452 | 2003-12-04 | ||
JP2003405436A JP2005162684A (ja) | 2003-12-04 | 2003-12-04 | 抗血栓組成物 |
JP2003-405436 | 2003-12-04 | ||
JP2003-421762 | 2003-12-19 | ||
JP2003421803A JP2005179252A (ja) | 2003-12-19 | 2003-12-19 | 血栓形成抑制剤 |
JP2003-421765 | 2003-12-19 | ||
JP2003-421803 | 2003-12-19 | ||
JP2003421765A JP2005179251A (ja) | 2003-12-19 | 2003-12-19 | 抗血小板凝集用組成物 |
JP2003421762A JP2005179250A (ja) | 2003-12-19 | 2003-12-19 | 抗血小板凝集組成物 |
JP2004-183472 | 2004-06-22 | ||
JP2004183472A JP2006008529A (ja) | 2004-06-22 | 2004-06-22 | フィブリン形成阻害組成物 |
JP2004-273361 | 2004-09-21 | ||
JP2004273336A JP2006089383A (ja) | 2004-09-21 | 2004-09-21 | 血栓予防組成物 |
JP2004273361A JP2006089384A (ja) | 2004-09-21 | 2004-09-21 | 血栓予防用組成物 |
JP2004-273336 | 2004-09-21 | ||
JP2004-328521 | 2004-11-12 | ||
JP2004-328536 | 2004-11-12 | ||
JP2004328531A JP2006137699A (ja) | 2004-11-12 | 2004-11-12 | 血小板凝集血栓抑制組成物 |
JP2004-328534 | 2004-11-12 | ||
JP2004328534A JP2006137700A (ja) | 2004-11-12 | 2004-11-12 | 血小板凝集血栓抑制用組成物 |
JP2004328529A JP2006137698A (ja) | 2004-11-12 | 2004-11-12 | 血小板凝集予防用組成物 |
JP2004-328531 | 2004-11-12 | ||
JP2004328526A JP2006137697A (ja) | 2004-11-12 | 2004-11-12 | 血小板凝集予防組成物 |
JP2004328522A JP2006137696A (ja) | 2004-11-12 | 2004-11-12 | 抗血液凝固組成物 |
JP2004328521A JP2006137695A (ja) | 2004-11-12 | 2004-11-12 | 外因系凝固予防組成物 |
JP2004-328526 | 2004-11-12 | ||
JP2004-328529 | 2004-11-12 | ||
JP2004328536A JP2006137701A (ja) | 2004-11-12 | 2004-11-12 | 血小板凝集抑制組成物 |
JP2004-328522 | 2004-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005058339A1 true WO2005058339A1 (ja) | 2005-06-30 |
Family
ID=34705494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017780 WO2005058339A1 (ja) | 2003-12-04 | 2004-11-30 | 血栓形成抑制用組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7914830B2 (ja) |
EP (1) | EP1721533A4 (ja) |
CA (1) | CA2547590A1 (ja) |
TW (1) | TW200533365A (ja) |
WO (1) | WO2005058339A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009136234A (ja) * | 2007-12-10 | 2009-06-25 | Kikkoman Corp | 酵素を用いた植物組織の可溶化方法及び混合酵素製剤 |
CN101250232B (zh) * | 2008-03-27 | 2010-06-23 | 钱国英 | 一种羊栖菜活性多糖的提取工艺 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130184359A1 (en) * | 2012-01-13 | 2013-07-18 | Karim Nafisi-Movaghar | Processes for Extracting Colors from Hibiscus Plants |
US20140212405A1 (en) * | 2013-01-28 | 2014-07-31 | 2294719 Ontario Limited | Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1278433A (zh) * | 2000-04-26 | 2001-01-03 | 中国科学院昆明植物研究所 | 一种溶栓药物,其制备方法及其用途 |
US6290996B1 (en) * | 1999-02-17 | 2001-09-18 | Natreon Inc. | Method of inhibiting blood platelet aggregation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002171934A (ja) | 2000-12-05 | 2002-06-18 | Takahisa Shioda | タマネギの薄皮(表皮)を原材料とする健康補助食品の製造方法。 |
JP2003171294A (ja) | 2001-12-04 | 2003-06-17 | Nof Corp | 血栓抑制剤および組成物 |
JP2004065047A (ja) | 2002-08-02 | 2004-03-04 | Honda Trading Corp | ナットウキナーゼの抽出方法及び抽出されたナットウキナーゼ |
US6776979B2 (en) * | 2002-12-30 | 2004-08-17 | Marvin B. Frager | Periodontal treatment compound and method of use |
-
2004
- 2004-11-30 US US10/581,287 patent/US7914830B2/en not_active Expired - Fee Related
- 2004-11-30 EP EP04820510A patent/EP1721533A4/en not_active Withdrawn
- 2004-11-30 CA CA002547590A patent/CA2547590A1/en not_active Abandoned
- 2004-11-30 WO PCT/JP2004/017780 patent/WO2005058339A1/ja active Application Filing
- 2004-12-03 TW TW093137554A patent/TW200533365A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6290996B1 (en) * | 1999-02-17 | 2001-09-18 | Natreon Inc. | Method of inhibiting blood platelet aggregation |
CN1278433A (zh) * | 2000-04-26 | 2001-01-03 | 中国科学院昆明植物研究所 | 一种溶栓药物,其制备方法及其用途 |
Non-Patent Citations (3)
Title |
---|
BORDIA, A. ET AL.: "Comparative effect of vitamin C, amla juice and amla pulp on b", INDIAN HEART JOURNAL., vol. 37, no. 3, 1985, pages 179 - 182 * |
DATABASE MEDLINE [online] 1985, BORDIA, A. ET AL.: "Comparative effect of vitamin C, amla juice and amla pulp on blood lipids, platelet aggregation and experimental atheroma in rabbits.", XP002987573, Database accession no. (4065917) * |
See also references of EP1721533A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009136234A (ja) * | 2007-12-10 | 2009-06-25 | Kikkoman Corp | 酵素を用いた植物組織の可溶化方法及び混合酵素製剤 |
CN101250232B (zh) * | 2008-03-27 | 2010-06-23 | 钱国英 | 一种羊栖菜活性多糖的提取工艺 |
Also Published As
Publication number | Publication date |
---|---|
CA2547590A1 (en) | 2005-06-30 |
EP1721533A4 (en) | 2007-11-28 |
US20080317774A1 (en) | 2008-12-25 |
US7914830B2 (en) | 2011-03-29 |
EP1721533A1 (en) | 2006-11-15 |
TW200533365A (en) | 2005-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101018403B1 (ko) | 콩잎 추출물을 유효성분으로 함유하는 통풍 예방,지연 또는 치료용 조성물 | |
WO2005058339A1 (ja) | 血栓形成抑制用組成物 | |
KR101976201B1 (ko) | 생강싹 추출물을 포함하는 항균 조성물 | |
KR102438938B1 (ko) | 바이탈멜론 (kctc14699bp) 및 이의 추출물을 포함하는 항비만용 조성물 | |
KR20190020889A (ko) | 아피오스 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
JP2006335709A (ja) | 組織因子阻害組成物、及びそれを含有する飲食品、飼料、医薬部外品、医薬品 | |
KR102085436B1 (ko) | 생누에를 이용한 식품원료의 가공방법 | |
KR101018404B1 (ko) | 정금나무 잎 추출물을 유효성분으로 함유하는 콜레스테롤 저하용 조성물 | |
KR20070017309A (ko) | 혈전 형성 억제용 조성물 | |
KR100656241B1 (ko) | 고지혈증 및 혈소판 응집에 대해 억제작용을 갖는대두발효 추출물과 이를 이용한 조성물 | |
JP2006335728A (ja) | 血液凝固抑制組成物 | |
JP2005162684A (ja) | 抗血栓組成物 | |
KR101889434B1 (ko) | 흑우엉 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
KR102149253B1 (ko) | 붓기 제거에 효과가 있는 식물성 천연물의 혼합 추출물을 포함하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
JP2010213609A (ja) | ガジュツ又はキョウオウの醗酵処理物 | |
JP2006008529A (ja) | フィブリン形成阻害組成物 | |
JP2006137697A (ja) | 血小板凝集予防組成物 | |
KR20240044080A (ko) | 호두잎 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
JP2006089384A (ja) | 血栓予防用組成物 | |
JP2024000101A (ja) | 破骨細胞分化抑制剤 | |
KR20230104839A (ko) | 천연 추출물의 발효액을 함유하는 기능성 식품 조성물및 이의 제조방법 | |
KR101040923B1 (ko) | 페피노 및 실크펩타이드를 유효성분으로 포함하는 간 기능 개선용 조성물 | |
JP2006137699A (ja) | 血小板凝集血栓抑制組成物 | |
KR20240044099A (ko) | 호두 착유박 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
JP2006137700A (ja) | 血小板凝集血栓抑制用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480041388.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2547590 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004820510 Country of ref document: EP Ref document number: 1020067013370 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004820510 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581287 Country of ref document: US |